

EXHIBIT A

**A MARKED UP VERSION OF THE PARAGRAPHS & TABLES AMENDED
IN THE SPECIFICATION
IN THE AMENDMENT FILED NOVEMBER 23, 2001**

**IN U.S. APPLICATION SERIAL NO. 09/724,396
ATTORNEY DOCKET NO. 10271-007**

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 17, line 14 of the specification:

In a specific embodiment, the present invention provides methods for preventing, treating or ameliorating one or more symptoms associated with a RSV infection in a mammal, said methods comprising administering to said mammal a first dose of one or more antibodies or fragments thereof comprising a VH domain having an amino acid sequence of SEQ ID NO:[11, 21, 31, 43, 51, 56, 61, 65, 70, 74, 85, 89, or 91] 7, 9, 16, 23, 28, 33, 36, 40, 44, 48, 51, 56 or 74 and/or a VL domain having an amino acid sequence of SEQ ID NO:[14, 23, 25, 28, 35, 37, 40, 47, 53, 57, 62, 67, 71, 76, 87, 90, or 94] 8, 12, 20, 25, 30, 34, 38, 42, 46, 52, 55, 57, 58, 60, 62, 64, 65, 75 to achieve a therapeutically or prophylactically effective serum titer, wherein said effective serum titer is less than 30 µg/ml (and is preferably at least 2 µg/ml, more preferably at least 4 µg/ml, and most preferably at least 6 µg/ml) after a certain number of days (for example, but not limited to, 20, 25, 30 or 35 days) without any other dosing within that period. In a preferred embodiment, the present invention provides methods for preventing, treating or ameliorating one or more symptoms associated with a RSV infection in a mammal, said methods comprising administering to said mammal a first dose of one or more antibodies or fragments thereof comprising a VH domain having an amino acid sequence of SEQ ID NO:[43, 51, 56, 61, 65, 74, 85, 89, or 93] 16, 23, 28, 33, 36, 40, 44, 48, or 51 and/or a VL domain having an amino acid sequence of SEQ ID NO:[47, 53, 57, 62, 67, 76, 87, 90, or 94] 20, 25, 30, 34, 38, 42, 46, 52, 75 or 52 to achieve a therapeutically or prophylactically effective serum titer, wherein said effective serum titer is less than 30 µg/ml (and is preferably at least 2 µg/ml, more preferably at least 4 µg/ml, and most preferably at least 6 µg/ml) after a certain number of days (for example, but not limited to, 20, 25, 30 or 35 days) without any other dosing within that period. In another embodiment, the present invention provides methods for preventing, treating or ameliorating one or more symptoms associated with a RSV infection in a mammal, said methods comprising administering to said mammal

a first dose of one or more antibodies or fragments thereof comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:[46 or 45] 19 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6 to a therapeutically or prophylactically effective serum titer, wherein said effective serum titer is less than 30 µg/ml (and is preferably at least 2 µg/ml, more preferably at least 4 µg/ml, and most preferably at least 6 µg/ml) after a certain number of days (for example, but not limited to, 20, 25, 30 or 35 days) without any other dosing within that period.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 44, line 27 of the specification:

In a specific embodiment, an antibody of the present invention is SYNAGIS® or an antibody-binding fragment thereof (*e.g.*, one or more complementarity determining regions (CDRs) of SYNAGIS®). The amino acid sequence of SYNAGIS® is disclosed, *e.g.*, in Johnson et al., 1997, J. Infectious Disease 176:1215-1224, and U.S. Patent No. 5,824,307[, and is also provided herein as SEQ ID NO:7]. In alternative embodiment, an antibody of the present invention or fragment thereof is not SYNAGIS® or a fragment of SYNAGIS®.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 45, line 26 of the specification:

In a specific embodiment, an antibody of the present invention comprises the amino acid sequence of [SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7. Preferably, an antibody of the present invention comprises the amino acid sequence of [SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7. In a preferred embodiment, an antibody of the present invention comprises a Fab fragment having the amino acid sequence of a Fab fragment having the amino acid sequence of [SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:69, SEQ ID NO:73, SEQ ID NO: 137, SEQ ID NO:222, or SEQ ID NO:223] 1X-493L2FR, H3-F4, M3H9, Y10H6, DG,

AFFF, 6H8, L1-7E5, L2-15B10, P12F2, P12F4, P11d4, Ale9, A12a6, A13a11, A13c4, A4B4, A17d4, or A8c7.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 46, line 1 of the specification:

In another embodiment, an antibody fragment of the present invention comprises the amino acid sequence of a portion of [SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7 that immunospecifically binds to a RSV antigen. In another embodiment, an antibody fragment of the present invention comprises a portion of a Fab fragment having the amino acid sequence of [~~SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:69, SEQ ID NO:73, SEQ ID NO:137, SEQ ID NO:222, or SEQ ID NO:223]~~ 1X-493L2FR, H3-3F4, M3H9, Y10H6, DG, 6H8, L1-7E5, L2-15B10, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13a11, A13c4, A4B4, A17d4, or A8c7.

A marked up version of the replacement Table 2 showing the changes made relative to Table 2 beginning on page 47 of the specification (with the additions double underlined):

Table 2. Antibodies & Fragments Thereof

[MAb or Fabs] <u>ANTIBODY</u>	VH Domain	VH CDR1	VH CDR2	VH CDR3	VL Domain	VL CDR1	VL CDR2	VL CDR3
<u>**[SEQ ID NO:7]</u> <u>SYNAGIS®</u>	SEQ ID NO:[8] <u>7</u>	TSGMSVG (SEQ ID NO:1)	DIWWDKKDY NPSLKS (SEQ ID NO:2)	SMITNWFYFDV (SEQ ID NO:3)	SEQ ID NO:[9] <u>8</u>	KCQLSVGYMH (SEQ ID NO:4)	DTSKLAS (SEQ ID NO:5)	FQSGYPFT (SEQ ID NO:6)
<u>***[SEQ ID NO:10]</u> <u>AFF</u>	SEQ ID NO:[11] <u>9</u>	TAGMSVG (SEQ ID NO:[12] <u>10</u>)	DIWWDKKDYN PSLKS (SEQ ID NO:2)	SMITNWFYFDV (SEQ ID NO:[13] <u>11</u>)	SEQ ID NO:[14] <u>12</u>	<u>S</u> A <u>S</u> <u>S</u> <u>S</u> SVGYMH (SEQ ID NO:[15] <u>13</u>)	DTEKLAS (SEQ ID NO:[16] <u>14</u>)	FQSGYPFT (SEQ ID NO:[17] <u>15</u>)
<u>***[SEQ ID NO:78]</u> <u>P12F2</u>	SEQ ID NO:[43] <u>16</u>	TPGMSVG (SEQ ID NO:[44] <u>17</u>)	DIWWDKKHYN PSLK <u>D</u> (SEQ ID NO:[45] <u>18</u>)	<u>D</u> MIFN <u>F</u> YFDV (SEQ ID NO:[46] <u>19</u>)	SEQ ID NO:[47] <u>20</u>	<u>S</u> I <u>S</u> <u>S</u> <u>S</u> RVGYMH (SEQ ID NO:[48] <u>21</u>)	DTFY <u>L</u> <u>S</u> (SEQ ID NO:[49] <u>22</u>)	FQSGYPFT (SEQ ID NO:6)
<u>***[SEQ ID NO:79]</u> <u>P12F4</u>	SEQ ID NO:[51] <u>23</u>	TPGMSVG (SEQ ID NO:[44] <u>17</u>)	DIWWDGKKHYN PSLK <u>D</u> (SEQ ID NO:[52] <u>24</u>)	<u>D</u> MIFN <u>F</u> YFDV (SEQ ID NO:[46] <u>19</u>)	SEQ ID NO:[53] <u>25</u>	<u>S</u> I <u>S</u> <u>S</u> <u>S</u> RVGYMH (SEQ ID NO:[48] <u>21</u>)	DTRGL <u>P</u> <u>S</u> (SEQ ID NO:[54] <u>27</u>)	FQSGYPFT (SEQ ID NO:6)
<u>***[SEQ ID NO:80]</u> <u>P11d4</u>	SEQ ID NO:[56] <u>28</u>	TPGMSVG (SEQ ID NO:[44] <u>17</u>)	DIWWDGKKHYN PSLK <u>D</u> (SEQ ID NO:[52] <u>24</u>)	<u>D</u> MIFN <u>F</u> YFDV (SEQ ID NO:[32] <u>29</u>)	SEQ ID NO:[57] <u>30</u>	<u>S</u> P <u>S</u> <u>S</u> <u>S</u> RVGYMH (SEQ ID NO:[58] <u>31</u>)	DT <u>M</u> RLAS (SEQ ID NO:[59] <u>32</u>)	FQSGYPFT (SEQ ID NO:6)

***[SEQ ID NO:81] <u>A1e9</u>	SEQ ID NO:[61] <u>33</u>	T <u>A</u> GMSVG (SEQ ID NO:[12] <u>10</u>)	DIWWD <u>G</u> KK <u>H</u> YN PSLK <u>D</u> (SEQ ID NO:[52] <u>24</u>)	<u>D</u> MIFN <u>F</u> YFDV (SEQ ID NO:[32] <u>29</u>)	SEQ ID NO:[62] <u>34</u>	<u>S</u> I <u>S</u> SRVGYMH (SEQ ID NO:[48] <u>21</u>)	D <u>T</u> FKL <u>S</u> S (SEQ ID NO:[63] <u>35</u>)	FQSGYPFT (SEQ ID NO:6)
***[SEQ ID NO:82] <u>A12a6</u>	SEQ ID NO:[65] <u>36</u>	T <u>A</u> GMSVG (SEQ ID NO:[12] <u>10</u>)	DIWWD <u>G</u> KKDYN PSLK <u>D</u> (SEQ ID NO:[66] <u>37</u>)	<u>D</u> MIFN <u>F</u> YFDV (SEQ ID NO:[46] <u>19</u>)	SEQ ID NO:[67] <u>38</u>	<u>S</u> A <u>S</u> SRVGYMH (SEQ ID NO:[38] <u>39</u>)	D <u>T</u> FKL <u>S</u> S (SEQ ID NO:[68] <u>35</u>)	FQSGYPFT (SEQ ID NO:6)
***[SEQ ID NO:83] <u>A13C4</u>	SEQ ID NO:[74] <u>40</u>	T <u>A</u> GMSVG (SEQ ID NO:[12] <u>10</u>)	DIWWD <u>G</u> KKSYN PSLK <u>D</u> (SEQ ID NO:[75] <u>41</u>)	<u>D</u> MIFN <u>F</u> YFDV (SEQ ID NO:[46] <u>19</u>)	SEQ ID NO:[76] <u>42</u>	<u>S</u> I <u>S</u> SRVGYMH (SEQ ID NO:[48] <u>21</u>)	D <u>T</u> MY <u>Q</u> SS (SEQ ID NO:[77] <u>43</u>)	FQSGYPFT (SEQ ID NO:6)
***[SEQ ID NO:84] <u>A17d4</u>	SEQ ID NO:[85] <u>44</u>	T <u>A</u> GMSVG (SEQ ID NO:[12] <u>10</u>)	DIWWD <u>D</u> KK <u>S</u> Y NPSLK <u>D</u> (SEQ ID NO:[96] <u>45</u>)	<u>D</u> MIFN <u>F</u> YFDV (SEQ ID NO:[46] <u>19</u>)	SEQ ID NO:[87] <u>46</u>	<u>L</u> P <u>S</u> SRVGYMH (SEQ ID NO:[86] <u>47</u>)	D <u>T</u> MY <u>Q</u> SS (SEQ ID NO:[77] <u>43</u>)	FQSGYPFT (SEQ ID NO:6)
***[SEQ ID NO:88] <u>A4B4</u>	SEQ ID NO:[89] <u>48</u>	T <u>A</u> GMSVG (SEQ ID NO:[12] <u>10</u>)	DIWWD <u>D</u> KK <u>H</u> YNPSLK <u>D</u> (SEQ ID NO:[45] <u>18</u>)	<u>D</u> MIFN <u>F</u> YFDV (SEQ ID NO:[46] <u>19</u>)	SEQ ID NO:[90] <u>75</u>	<u>S</u> A <u>S</u> SRVGYMH (SEQ ID NO:[38] <u>73</u>)	D <u>T</u> LL <u>L</u> DS (SEQ ID NO:[91] <u>50</u>)	FQSGYPFT (SEQ ID NO:6)
***[SEQ ID NO:92] <u>A8c7</u>	SEQ ID NO:[93] <u>51</u>	T <u>A</u> GMSVG (SEQ ID NO:[12] <u>10</u>)	DIWWD <u>D</u> KK <u>S</u> Y NPSLK <u>D</u> (SEQ ID NO:[96] <u>45</u>)	<u>D</u> MIFN <u>F</u> YFDV (SEQ ID NO:[32] <u>29</u>)	SEQ ID NO:[94] <u>52</u>	<u>S</u> P <u>S</u> SRVGYMH (SEQ ID NO:[58] <u>53</u>)	D <u>T</u> RY <u>Q</u> SS (SEQ ID NO:[95] <u>54</u>)	FQSGYPFT (SEQ ID NO:6)

*[SEQ ID NO:18] IX-493L2FR	SEQ ID NO:[11] 7	TSGMSVG (SEQ ID NO:1)	DIWWDDKKDYN PSLKS (SEQ ID NO:2)	SMITNWFYFDV (SEQ ID NO:3)	SEQ ID NO:[19] 55	SASSSVGYMH (SEQ ID NO:[15] 13)	DTSKLAS (SEQ ID NO:5)	FQSGYPFT (SEQ ID NO:6)
*[SEQ ID NO:20] H3-3F4	SEQ ID NO:[21] 56	TAGMSVG (SEQ ID NO:[12] 10)	DIWWDDKKDYN PSLKS (SEQ ID NO:2)	DMIFNWFYFDV (SEQ ID NO:[32] 29)	SEQ ID NO:[23] 57	SASSSVGYMH (SEQ ID NO:[15] 13)	DTEKLAS (SEQ ID NO:[16] 14)	FQSGYPFT (SEQ ID NO:6)
*[SEQ ID NO:24] M3H9	SEQ ID NO:[21] 56	TAGMSVG (SEQ ID NO:[12] 10)	DIWWDDKKDYN PSLKS (SEQ ID NO:2)	DMIFNWFYFDV (SEQ ID NO:[32] 29)	SEQ ID NO:[25] 58	SASSSVGYMH (SEQ ID NO:[15] 13)	DTYKQTS (SEQ ID NO:[26] 59)	FQSGYPFT (SEQ ID NO:6)
*[SEQ ID NO:27] Y10H6	SEQ ID NO:[21] 56	TAGMSVG (SEQ ID NO:[12] 10)	DIWWDDKKDYN PSLKS (SEQ ID NO:2)	DMIFNWFYFDV (SEQ ID NO:[32] 29)	SEQ ID NO:[28] 60	SASSSVGYMH (SEQ ID NO:[15] 13)	DTRYLSS (SEQ ID NO:[29] 61)	FQSGYPFT (SEQ ID NO:6)
*[SEQ ID NO:30] DG	SEQ ID NO:[31] 74	TAGMSVG (SEQ ID NO:[12] 10)	DIWWDDKKDYN PSLKS (SEQ ID NO:2)	DMITNWFYFDV (SEQ ID NO:[32] 29)	SEQ ID NO:[23] 57	SASSSVGYMH (SEQ ID NO:[15] 13)	DTEKLAS (SEQ ID NO:[16] 14)	FQSGYPFT (SEQ ID NO:6)
*[SEQ ID NO:33]	[SEQ ID NO:11]	[TAGMSVG (SEQ ID NO:10)]	[DIWWDDKKDYN NPSLKS (SEQ ID NO:2)]	[SMITNWFYFDV (SEQ ID NO:13)]	[SEQ ID NO:14]	[SASSSVGYMH 66(SEQ ID NO:15)]	[DTEKLAS (SEQ ID NO:16)]	[FQSGYPFT (SEQ ID NO:17)]
*[SEQ ID NO:34] 6H8	SEQ ID NO:[31] 74	TAGMSVG (SEQ ID NO:[12] 10)	DIWWDDKKDYN PSLKS (SEQ ID NO:2)	DMITNWFYFDV (SEQ ID NO:[32] 29)	SEQ ID NO:[35] 62	SASSSVGYMH (SEQ ID NO:[15] 13)	DTEKLTS (SEQ ID NO:[103] 63)	FQSGYPFT (SEQ ID NO:6)
*[SEQ ID NO:36] L1-7E5	SEQ ID NO:[31] 74	TAGMSVG (SEQ ID NO:[12] 10)	DIWWDDKKDYN PSLKS (SEQ ID NO:2)	DMITNWFYFDV (SEQ ID NO:[32] 29)	SEQ ID NO:[37] 64	SASSRVGYMH (SEQ ID NO:[38] 39)	DTEKLAS (SEQ ID NO:[16] 14)	FQSGYPFT (SEQ ID NO:6)

*[SEQ ID NO:39] <u>L2-15B10</u>	SEQ ID NO:[31] <u>74</u>	TAGMSVG (SEQ ID NO:[12] <u>10</u>)	DIWWDKKDY N PSLKS (SEQ ID NO:2)	<u>DMITNFYFDV</u> (SEQ ID NO:26)	SEQ ID NO:[40] <u>65</u>	SASSVGYMH (SEQ ID NO:[15] <u>13</u>)	DTERLAS (SEQ ID NO:[41] <u>66</u>)	FQSGYPFT (SEQ ID NO:6)
*[SEQ ID NO:42]	[SEQ ID NO:43]	[TPGMSVG (SEQ ID NO:44)]	[DIWWDKKHY NPSLKD (SEQ ID NO:45)]	<u>IDMIFNYFDV</u> (SEQ ID NO:46)]	[SEQ ID NO:47]	[SLSSRVGYMH (SEQ ID NO:48)]	[DTFYLS (SEQ ID NO:49)]	[FQSGYPFT (SEQ ID NO:6)]
*[SEQ ID NO:50]	[SEQ ID NO:51]	[TPGMSVG (SEQ ID NO:44)]	[DIWWDGKKHY NPSLKD (SEQ ID NO:52)]	<u>IDMIFNYFDV</u> (SEQ ID NO:46)]	[SEQ ID NO:53]	[SLSSRVGYMH (SEQ ID NO:48)]	[DTRGLPS (SEQ ID NO:54)]	[FQSGYPFT (SEQ ID NO:6)]
*[SEQ ID NO:55]	[SEQ ID NO:56]	[TPGMSVG (SEQ ID NO:44)]	[DIWWDGKKHY NPSLKD (SEQ ID NO:52)]	<u>IDMIFNYFDV</u> (SEQ ID NO:32)]	[SEQ ID NO:57]	[SPSSRVGYMH (SEQ ID NO:58)]	[DTMLAS (SEQ ID NO:59)]	[FQSGYPFT (SEQ ID NO:6)]
*[SEQ ID NO:60]	[SEQ ID NO:61]	[TAGMSVG (SEQ ID NO:12)]	[DIWWDGKKHY NPSLKD (SEQ ID NO:52)]	<u>IDMIFNYFDV</u> (SEQ ID NO:32)]	[SEQ ID NO:62]	[SLSSRVGYMH (SEQ ID NO:48)]	[DTFKLS (SEQ ID NO:63)]	[FQSGYPFT (SEQ ID NO:6)]
*[SEQ ID NO:64]	[SEQ ID NO:65]	[TAGMSVG (SEQ ID NO:12)]	[DIWWDGKKDY NPSLKD (SEQ ID NO:66)]	<u>IDMIFNYFDV</u> (SEQ ID NO:46)]	[SEQ ID NO:67]	[SASSRVGYMH (SEQ ID NO:38)]	[DTFKLS (SEQ ID NO:68)]	[FQSGYPFT (SEQ ID NO:6)]
*[SEQ ID NO:69] <u>A13a11</u>	SEQ ID NO:[70] <u>67</u>	TAGMSVG (SEQ ID NO:[12] <u>10</u>)	DIWWDKKHY N PSLKD (SEQ ID NO:[52] <u>18</u>)	<u>IDMIFNYFDV</u> (SEQ ID NO:[32] <u>29</u>)	SEQ ID NO:[71] <u>68</u>	[SPSSRVGYMH (SEQ ID NO:[58] <u>31</u>)	DTYRHSS (SEQ ID NO:[72] <u>69</u>)	FQSGYPFT (SEQ ID NO:6)
*[SEQ ID NO:222]	[SEQ ID NO:85]	[TAGMSVG (SEQ ID NO:12)]	[DIWWDKKSY NPSLKD (SEQ ID NO:96)]	<u>IDMIFNYFDV</u> (SEQ ID NO:46)]	[SEQ ID NO:87]	[LPSSRVGYMH (SEQ ID NO:86)]	[DTMYQSS (SEQ ID NO:77)]	[FQSGYPFT (SEQ ID NO:6)]

*[SEQ ID NO:223]	[SEQ ID NO:93]	[TAGMSVG (SEQ ID NO:12)]	[DIWWDKKK S YNPSLK D (SEQ ID NO:96)]	[DMIFNWFYFDV (SEQ ID NO:32)]	[SEQ ID NO:94]	[SPSSRVGYMHW (SEQ ID NO:58)]	[DTRYQSS (SEQ ID NO:95)]	[FQSGYPFT (SEQ ID NO:6)]
*[SEQ ID NO:225] <u>Alh₅</u>	SEQ ID NO:[61] <u>33</u>	TAGMSVG (SEQ ID NO:[12] <u>10</u>)	DIWWDGKKHYN PSLK D (SEQ ID NO:[52] <u>24</u>)	DMIFNWFYFDV (SEQ ID NO:[32] <u>29</u>)	SEQ ID NO:[226] <u>70</u>	SLSSRVGYMH (SEQ ID NO:[128] <u>71</u>)	DTEFHRS (SEQ ID NO:[227] <u>72</u>)	FQSGYPFT (SEQ ID NO:6)
*[SEQ ID NO:137]	[SEQ ID NO:89]	[TAGMSVG (SEQ ID NO:12)]	[DIWWDKKKH YNPSLK D (SEQ ID NO:45)]	[DMIFNWFYFDV (SEQ ID NO:46)]	[SEQ ID NO:90]	[SASSRVGYMHW (SEQ ID NO:38)]	[DTLLLD S (SEQ ID NO:91)]	[FQSGYPFT (SEQ ID NO:6)]
*[SEQ ID NO:73]	[SEQ ID NO:74]	[TAGMSVG (SEQ ID NO:12)]	[DIWWDKKKSYN PSLK D (SEQ ID NO:96)]	[DMIFNWFYFDV (SEQ ID NO:46)]	[SEQ ID NO:76]	[SLSSRVGYMH (SEQ ID NO:48)]	[DTMYQSS (SEQ ID NO:77)]	[FQSGYPFT (SEQ ID NO:6)]

Bold faced & underlined amino acid residues are the residues which differ from the amino acid residues in SYNAGISTM®; Fab fragment (*); Monoclonal antibody (**); Monoclonal Antibody & Fab fragment (***)

A marked up version of the replacement Table 3 showing the changes made relative to Table 3 beginning on page 51 of the specification (with the additions double underlined):

Table 3. CDR Sequences

VH CDR1	VH CDR2	VH CDR3	VL CDR1	VL CDR2	VL CDR3
TSGMSVG (SEQ ID NO:1)	DIWWDGKKDYNPSLK S (SEQ ID NO:2)	SMTNWFYFDV (SEQ ID NO:3)	KCOLSVGYMH (SEQ ID NO:4)	DTSKLAS (SEQ ID NO:5)	FQSGYPFT (SEQ ID NO:6)

TPGMSVG (SEQ ID NO:[44] <u>17</u>)	DIWWD $\overline{\text{D}}$ KK $\overline{\text{H}}$ YNPSLK $\overline{\text{D}}$ (SEQ ID NO:[45] <u>18</u>)	$\overline{\text{D}}$ MI $\overline{\text{T}}$ N $\overline{\text{F}}$ YFDV (SEQ ID NO:[22] <u>76</u>)	K $\overline{\text{C}}$ O $\overline{\text{S}}$ S $\overline{\text{V}}$ G $\overline{\text{Y}}$ M $\overline{\text{H}}$ (SEQ ID NO:[113] <u>77</u>)	D $\overline{\text{T}}$ S $\overline{\text{Y}}$ L $\overline{\text{A}}$ S (SEQ ID NO:[68] <u>78</u>)	
T $\overline{\text{A}}$ GMSVG (SEQ ID NO:[12] <u>10</u>)	DIWWD $\overline{\text{D}}$ KK $\overline{\text{H}}$ YNPSLK $\overline{\text{S}}$ (SEQ ID NO:[102] <u>79</u>)	$\overline{\text{D}}$ MI $\overline{\text{T}}$ N $\overline{\text{W}}$ YFDV (SEQ ID NO:[109] <u>80</u>)	K $\overline{\text{C}}$ O $\overline{\text{S}}$ R $\overline{\text{V}}$ G $\overline{\text{Y}}$ M $\overline{\text{H}}$ (SEQ ID NO:[114] <u>81</u>)	D $\overline{\text{T}}$ S $\overline{\text{Y}}$ L $\overline{\text{S}}$ (SEQ ID NO:[188] <u>82</u>)	
	DIWWD $\overline{\text{D}}$ KK $\overline{\text{D}}$ YNPSLK $\overline{\text{D}}$ (SEQ ID NO:[97] <u>83</u>)	$\overline{\text{D}}$ MI $\overline{\text{F}}$ N $\overline{\text{W}}$ YFDV (SEQ ID NO:[32] <u>29</u>)	K $\overline{\text{C}}$ O $\overline{\text{L}}$ R $\overline{\text{V}}$ G $\overline{\text{Y}}$ M $\overline{\text{H}}$ (SEQ ID NO:[115] <u>84</u>)	D $\overline{\text{T}}$ K $\overline{\text{K}}$ L $\overline{\text{S}}$ (SEQ ID NO:[189] <u>85</u>)	
	DIWWD $\overline{\text{D}}$ KK $\overline{\text{H}}$ YNPSLK $\overline{\text{D}}$ (SEQ ID NO:[98] <u>18</u>)	$\overline{\text{D}}$ MI $\overline{\text{F}}$ N $\overline{\text{F}}$ YFDV (SEQ ID NO:[46] <u>19</u>)	K $\overline{\text{L}}$ O $\overline{\text{L}}$ S $\overline{\text{V}}$ G $\overline{\text{Y}}$ M $\overline{\text{H}}$ (SEQ ID NO:[116] <u>86</u>)	D $\overline{\text{T}}$ F $\overline{\text{Y}}$ L $\overline{\text{S}}$ (SEQ ID NO:49)	
	DIWWD $\overline{\text{D}}$ KK $\overline{\text{H}}$ YNPSLK $\overline{\text{S}}$ (SEQ ID NO:[99] <u>87</u>)	$\overline{\text{S}}$ MI $\overline{\text{T}}$ N $\overline{\text{F}}$ YFDV (SEQ ID NO:[13] <u>11</u>)	K $\overline{\text{L}}$ O $\overline{\text{S}}$ S $\overline{\text{V}}$ G $\overline{\text{Y}}$ M $\overline{\text{H}}$ (SEQ ID NO:[117] <u>88</u>)	D $\overline{\text{T}}$ F $\overline{\text{K}}$ L $\overline{\text{A}}$ S (SEQ ID NO:[16] <u>14</u>)	
	DIWWD $\overline{\text{D}}$ KK $\overline{\text{D}}$ YNPSLK $\overline{\text{D}}$ (SEQ ID NO:[100] <u>89</u>)	$\overline{\text{S}}$ MI $\overline{\text{F}}$ N $\overline{\text{W}}$ YFDV (SEQ ID NO:[111] <u>90</u>)	K $\overline{\text{L}}$ O $\overline{\text{S}}$ R $\overline{\text{V}}$ G $\overline{\text{Y}}$ M $\overline{\text{H}}$ (SEQ ID NO:[118] <u>91</u>)	D $\overline{\text{T}}$ F $\overline{\text{K}}$ L $\overline{\text{S}}$ (SEQ ID NO:[63] <u>35</u>)	
	DIWWD $\overline{\text{G}}$ KK $\overline{\text{H}}$ YNPSLK $\overline{\text{D}}$ (SEQ ID NO:[52] <u>24</u>)	$\overline{\text{S}}$ MI $\overline{\text{F}}$ N $\overline{\text{F}}$ YFDV (SEQ ID NO:[112] <u>92</u>)	K $\overline{\text{L}}$ O $\overline{\text{L}}$ R $\overline{\text{V}}$ G $\overline{\text{Y}}$ M $\overline{\text{H}}$ (SEQ ID NO:[119] <u>93</u>)	D $\overline{\text{T}}$ F $\overline{\text{Y}}$ L $\overline{\text{A}}$ S (SEQ ID NO:[191] <u>94</u>)	
	DIWWD $\overline{\text{G}}$ KK $\overline{\text{D}}$ YNPSLK $\overline{\text{S}}$ (SEQ ID NO:[101] <u>95</u>)		K $\overline{\text{L}}$ S $\overline{\text{L}}$ S $\overline{\text{V}}$ G $\overline{\text{Y}}$ M $\overline{\text{H}}$ (SEQ ID NO:[120] <u>96</u>)	D $\overline{\text{T}}$ S $\overline{\text{K}}$ L $\overline{\text{P}}$ S (SEQ ID NO:[192] <u>97</u>)	
	DIWWD $\overline{\text{G}}$ KK $\overline{\text{D}}$ YNPSLK $\overline{\text{D}}$ (SEQ ID NO:[66] <u>37</u>)		K $\overline{\text{L}}$ S $\overline{\text{S}}$ S $\overline{\text{V}}$ G $\overline{\text{Y}}$ M $\overline{\text{H}}$ (SEQ ID NO:[121] <u>98</u>)	D $\overline{\text{T}}$ S $\overline{\text{G}}$ L $\overline{\text{A}}$ S (SEQ ID NO:[193] <u>99</u>)	
	DIWWD $\overline{\text{G}}$ KK $\overline{\text{H}}$ YNPSLK $\overline{\text{S}}$ (SEQ ID NO:[105] <u>95</u>)		K $\overline{\text{L}}$ S $\overline{\text{S}}$ R $\overline{\text{V}}$ G $\overline{\text{Y}}$ M $\overline{\text{H}}$ (SEQ ID NO:[122] <u>101</u>)	D $\overline{\text{T}}$ S $\overline{\text{G}}$ L $\overline{\text{P}}$ S (SEQ ID NO:[194] <u>102</u>)	
	DIWWD $\overline{\text{D}}$ KK $\overline{\text{S}}$ YNPSLK $\overline{\text{S}}$ (SEQ ID NO:[104] <u>103</u>)		K $\overline{\text{L}}$ S $\overline{\text{L}}$ R $\overline{\text{V}}$ G $\overline{\text{Y}}$ M $\overline{\text{H}}$ (SEQ ID NO:[123] <u>104</u>)	D $\overline{\text{T}}$ R $\overline{\text{G}}$ L $\overline{\text{P}}$ S (SEQ ID NO:[54] <u>27</u>)	

	DIWWD D KK S YNPSLK D (SEQ ID NO:[96] 105)		<u>KCSLS</u> VG Y M H (SEQ ID NO:[124] 106)	D T R K L A S (SEQ ID NO:[195] 107)	
	DIWWDG G KK S YNPSLK S (SEQ ID NO:[106] 108)		<u>KCSSS</u> VG Y M H (SEQ ID NO:[125] 109)	D T R G L A S (SEQ ID NO:[196] 110)	
	DIWWDG G KK S YNPSLK D (SEQ ID NO:[75] 41)		<u>KCSSR</u> VG Y M H (SEQ ID NO:[126] 111)	D T R K L P S (SEQ ID NO:[224] 112)	
			<u>KCSLR</u> VG Y M H (SEQ ID NO:[126] 113)	D T M R L A S (SEQ ID NO:[59] 32)	
			<u>SLSL</u> SVG Y M H (SEQ ID NO:[127] 114)	D T M K L A S (SEQ ID NO:[197] 115)	
			<u>SLSSS</u> VG Y M H (SEQ ID NO:[128] 116)	D T S R L A S (SEQ ID NO:[198] 117)	
			<u>SLSSR</u> VG Y M H (SEQ ID NO:[48] 21)	D T S L L A S (SEQ ID NO:[199] 118)	
			<u>SLSLR</u> VG Y M H (SEQ ID NO:[129] 119)	D T S L L D S (SEQ ID NO:[200] 120)	
			<u>SCOLS</u> VG Y M H (SEQ ID NO:[130] 121)	D T S K L D S (SEQ ID NO:[201] 122)	
			<u>SCOSS</u> VG Y M H (SEQ ID NO:[131] 123)	D T L L L D S (SEQ ID NO:[91] 124)	
			<u>SCOSR</u> VG Y M H (SEQ ID NO:[132] 125)	D T L K L D S (SEQ ID NO:[202] 126)	
			<u>SCOLR</u> VG Y M H (SEQ ID NO:[133] 127)	D T L L L A S (SEQ ID NO:[203] 128)	

			<u>SLQLSVGYMH</u> (SEQ ID NO:[134] 129)	<u>DTLKLAS</u> (SEQ ID NO:[204] 130)	
			<u>SLOSSVGYMH</u> (SEQ ID NO:[135] 131)	<u>DTSKLSS</u> (SEQ ID NO:[205] 132)	
			<u>SLOSRVGYMH</u> (SEQ ID NO:[136] 133)	<u>DTSKOAS</u> (SEQ ID NO:[206] 134)	
			<u>SLQLRVGYMH</u> (SEQ ID NO:[138] 135)	<u>DTSKOSS</u> (SEQ ID NO:[207] 136)	
			<u>SCSLSVGYMH</u> (SEQ ID NO:[139] 137)	<u>DTSYLAS</u> (SEQ ID NO:[208] 138)	
			<u>SCSSSVGYMH</u> (SEQ ID NO:[140] 139)	<u>DTSYLSS</u> (SEQ ID NO:[209] 140)	
			<u>SCSSRVGYMH</u> (SEQ ID NO:141)	<u>DTSYQAS</u> (SEQ ID NO:[210] 142)	
			<u>SCSLRVGYMH</u> (SEQ ID NO:[142] 143)	<u>DTSYQSS</u> (SEQ ID NO:[211] 144)	
			<u>KPSSRVGYMH</u> (SEQ ID NO:[143] 145)	<u>DTMYOAS</u> (SEQ ID NO:[212] 146)	
			<u>KPSLRVGYMH</u> (SEQ ID NO:[144] 147)	<u>DTMYOSS</u> (SEQ ID NO:[217] 43)	
			<u>KPSSSVGYMH</u> (SEQ ID NO:[145] 148)	<u>DTMKOAS</u> (SEQ ID NO:[213] 149)	
			<u>KPSLSVGYMH</u> (SEQ ID NO:[146] 150)	<u>DTMKOSS</u> (SEQ ID NO:[214] 151)	

			<u>KPOS</u>RVGYMH (SEQ ID NO:[147] <u>152</u>)	<u>DTMY</u>LAS (SEQ ID NO:[215] <u>153</u>)	
			<u>KPOL</u>RVGYMH (SEQ ID NO:[148] <u>154</u>)	<u>DTMY</u>LSS (SEQ ID NO:[216] <u>155</u>)	
			<u>KPOSS</u>VGVMH (SEQ ID NO:[149] <u>156</u>)	<u>DTMK</u>LAS (SEQ ID NO:[217] <u>157</u>)	
			<u>KPOL</u>SVGYMH (SEQ ID NO:[150] <u>158</u>)	<u>DTMK</u>LSS (SEQ ID NO:[218] <u>159</u>)	
			<u>SPSS</u>RVGYMH (SEQ ID NO:[151] <u>160</u>)	<u>DTSK</u>LSS (SEQ ID NO:[219] <u>161</u>)	
			<u>SPSL</u>RVGYMH (SEQ ID NO:[152] <u>162</u>)	<u>DTRY</u>OAS (SEQ ID NO:[220] <u>163</u>)	
			<u>SPSS</u>SVGYMH (SEQ ID NO:[153] <u>164</u>)	<u>DTRY</u>QSS (SEQ ID NO:[95] <u>54</u>)	
			<u>SPSL</u>SVGYMH (SEQ ID NO:[154] <u>165</u>)	<u>DTRK</u>OAS (SEQ ID NO:[221] <u>166</u>)	
			<u>SPOS</u>RVGYMH (SEQ ID NO:[155] <u>167</u>)	<u>DTRK</u>OSS (SEQ ID NO:[190] <u>168</u>)	
			<u>SPOL</u>RVGYMH (SEQ ID NO:[156] <u>169</u>)	<u>DTRK</u>LAS (SEQ ID NO:[107] <u>170</u>)	
			<u>SPOSS</u>VGVMH (SEQ ID NO:[157] <u>171</u>)	<u>DTRK</u>LSS (SEQ ID NO:[108] <u>172</u>)	
			<u>SPOL</u>SVGYMH (SEQ ID NO:[158] <u>173</u>)	<u>DTRY</u>LAS (SEQ ID NO:[110] <u>174</u>)	

			<u>KAOSRVGYMH</u> (SEQ ID NO:[159] 175)	<u>DTRYLSS</u> (SEQ ID NO:[29]177)	
			<u>KAOLRVGYMH</u> (SEQ ID NO:[160] 176)		
			<u>KAOSSVGYMH</u> (SEQ ID NO:[161] 178)		
			<u>KAOLSVGYMH</u> (SEQ ID NO:[162] 179)		
			<u>KASSRVGYMH</u> (SEQ ID NO:[163] 180)		
			<u>KASLRVGYMH</u> (SEQ ID NO:[164] 181)		
			<u>KASSSVGYMH</u> (SEQ ID NO:[165] 182)		
			<u>KASLSVGYMH</u> (SEQ ID NO:[166] 183)		
			<u>SASSRVGYMH</u> (SEQ ID NO:[38] 39)		
			<u>SASLRVGYMH</u> (SEQ ID NO:[167] 184)		
			<u>SASSSVGYMH</u> (SEQ ID NO:[15] 13)		
			<u>SASLSVGYMH</u> (SEQ ID NO:[168] 185)		

			<u>SAQSR</u> VG Y M H (SEQ ID NO:[169] <u>186</u>)			
			<u>SAQLR</u> VG Y M H (SEQ ID NO:[170] <u>187</u>)			
			<u>SAQSS</u> VG Y M H (SEQ ID NO:[171] <u>188</u>)			
			<u>LPSSR</u> VG Y M H (SEQ ID NO:[86] <u>47</u>)			
			<u>LPSL</u> S V G Y M H (SEQ ID NO:[172] <u>189</u>)			
			<u>LPSSS</u> VG Y M H (SEQ ID NO:[173] <u>190</u>)			
			<u>LPSLR</u> VG Y M H (SEQ ID NO:[174] <u>191</u>)			
			<u>LCSSR</u> VG Y M H (SEQ ID NO:[175] <u>192</u>)			
			<u>LCSL</u> S V G Y M H (SEQ ID NO:[176] <u>193</u>)			
			<u>LCSSS</u> VG Y M H (SEQ ID NO:[177] <u>194</u>)			
			<u>LCSLR</u> VG Y M H (SEQ ID NO:[178] <u>195</u>)			
			<u>LPOSR</u> VG Y M H (SEQ ID NO:[179] <u>196</u>)			

			<u>LPQLSVGYMH</u> (SEQ ID NO:[180] 197)		
			<u>LPOSSVGYMH</u> (SEQ ID NO:[181] 198)		
			<u>LPQLRVGYMH</u> (SEQ ID NO:[182] 199)		
			<u>LCQSRVGYMH</u> (SEQ ID NO:[183] 200)		
			<u>LCQLSVGYMH</u> (SEQ ID NO:[184] 201)		
			<u>LCQSSVGYMH</u> (SEQ ID NO:[185] 202)		
			<u>LCQLRVGYMH</u> (SEQ ID NO:[186] 203)		
			<u>SAQLSVGYMH</u> (SEQ ID NO:[187] 204)		

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 58, line 1 of the specification:

In one embodiment of the present invention, antibodies or fragments thereof comprise a VH CDR1 having the amino acid sequence of SEQ ID NO:1, [SEQ ID NO:12, or SEQ ID NO:44] SEQ ID NO:10 or SEQ ID NO:17. In another embodiment, antibodies or fragments thereof comprise a VH CDR2 having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:37, SEQ ID NO:41 or SEQ ID NO:45. In another embodiment, antibodies comprise a VH CDR3 having the amino acid sequence of SEQ ID NO:3, [SEQ ID NO:13, SEQ ID NO:22, SEQ ID NO:32 or SEQ ID NO:46] SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:26 or SEQ ID NO:29. In a preferred embodiment, antibodies or fragments thereof comprise a VH CDR1 having the amino acid sequence of SEQ ID NO:1, [SEQ ID NO:12 or SEQ ID NO:44] SEQ ID NO:10 or SEQ ID NO:17, a VH CDR2 having the amino acid sequence of SEQ ID NO:2, [SEQ ID NO:45, SEQ ID NO:52, SEQ ID NO:66, SEQ ID NO:75 or SEQ ID NO:96] SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:37, SEQ ID NO:41 or SEQ ID NO:45, and a VH CDR3 having the amino acid sequence of SEQ ID NO:3, [SEQ ID NO:13, SEQ ID NO:22, SEQ ID NO:32 or SEQ ID NO:46] SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:26 or SEQ ID NO:29.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 58, line 20 of the specification:

In one embodiment of the present invention, antibodies or fragments thereof comprise a VL CDR1 having the amino acid sequence of SEQ ID NO:4, [SEQ ID NO:15, SEQ ID NO:38, SEQ ID NO:48, SEQ ID NO:58 or SEQ ID NO:86] SEQ ID NO:13, SEQ ID NO: 21, SEQ ID NO:31, SEQ ID NO: 39, SEQ ID NO:47, SEQ ID NO: 53 or SEQ ID NO: 73. In another embodiment, antibodies or fragments thereof comprise a VL CDR2 having the amino acid sequence of SEQ ID NO:5, [SEQ ID NO:16, SEQ ID NO:26, SEQ ID NO:29,, SEQ ID NO:41, SEQ ID NO:49, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:63, SEQ ID NO:72, SEQ ID NO:77, SEQ ID NO:91, SEQ ID NO:95 or SEQ ID NO:103] SEQ ID NO:14, SEQ ID NO:22, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69 or SEQ ID NO:72. In another embodiment, antibodies or fragments thereof comprise a VL CDR3 having the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:[17] 15. In a preferred embodiment, antibodies or fragments

thereof comprise a VL CDR1 having the amino acid sequence of SEQ ID NO:4, [SEQ ID NO:15, SEQ ID NO:38, SEQ ID NO:48, SEQ ID NO:58 or SEQ ID NO:86] SEQ ID NO:13, SEQ ID NO: 21, SEQ ID NO:31, SEQ ID NO: 39, SEQ ID NO:47, SEQ ID NO: 53 or SEQ ID NO: 73, a VL CDR2 having the amino acid sequence of SEQ ID NO:5, [SEQ ID NO:16, SEQ ID NO:26, SEQ ID NO:29,, SEQ ID NO:41, SEQ ID NO:49, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:63, SEQ ID NO:72, SEQ ID NO:77, SEQ ID NO:91, SEQ ID NO:95 or SEQ ID NO:103] SEQ ID NO:14, SEQ ID NO:22, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69 or SEQ ID NO:72, and a VL CDR3 having the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:[17] 15.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 59, line 1 of the specification:

The present invention also provides antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, said antibodies or antibody fragments comprising a VH domain disclosed herein combined with a VL domain disclosed herein, or other VL domain. The present invention further provides antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, said antibodies or fragments comprising a VL domain disclosed herein combined with a VH domain disclosed herein, or other VH domain. In a preferred embodiment, antibodies or fragments thereof that immunospecifically bind to a RSV antigen comprise a VH domain having the amino acid sequence of [SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:21, SEQ ID NO:31, SEQ ID NO:43, SEQ ID NO:51, SEQ ID NO:56, SEQ ID NO:61, SEQ ID NO:65, SEQ ID NO:70, SEQ ID NO:74, SEQ ID NO:85, SEQ ID NO:89 or SEQ ID NO:93] SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:16, SEQ ID NO:23, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:48, SEQ ID NO:51, SEQ ID NO:56, SEQ ID NO:67 or SEQ ID NO:74 and a VL domain having the amino acid sequence of [SEQ ID NO:9, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:28, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:40, SEQ ID NO:47, SEQ ID NO:53, SEQ ID NO:57, SEQ ID NO:62, SEQ ID NO:67, SEQ ID NO:71, SEQ ID NO:76, SEQ ID NO:87, SEQ ID NO:90 or SEQ ID NO:94] SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:38, SEQ ID NO:42, SEQ ID NO:46, SEQ ID

NO:52, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:68, SEQ ID NO:70 or SEQ ID NO:75.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 59, line 16 of the specification:

The present invention also provides antibodies or fragments thereof comprising one or more VH CDRs and one or more VL CDRs listed in Table 2 and/or Table 3. In particular, the invention provides for an antibody or fragment thereof comprising a VH CDR1 and a VL CDR1, a VH CDR1 and a VL CDR2, a VH CDR1 and a VL CDR3, a VH CDR2 and a VL CDR1, VH CDR2 and VL CDR2, a VH CDR2 and a VL CDR3, a VH CDR3 and a VH CDR1, a VH CDR3 and a VL CDR2, a VH CDR3 and a VL CDR3, or any combination thereof of the VH CDRs and VL CDRs listed in Table 2. The invention also provides for an antibody or fragment thereof comprising a VH CDR1 and a VL CDR1, a VH CDR1 and a VL CDR2, a VH CDR1 and a VL CDR3, a VH CDR2 and a VL CDR1, VH CDR2 and VL CDR2, a VH CDR2 and a VL CDR3, a VH CDR3 and a VH CDR1, a VH CDR3 and a VL CDR2, a VH CDR3 and a VL CDR3, or any combination thereof of the VH CDRs and VL CDRs listed in Table 3. The invention also provides for an antibody or fragment thereof comprising a VH CDR1 and a VL CDR1, a VH CDR1 and a VL CDR2, a VH CDR1 and a VL CDR3, a VH CDR2 and a VL CDR1, VH CDR2 and VL CDR2, a VH CDR2 and a VL CDR3, a VH CDR3 and a VH CDR1, a VH CDR3 and a VL CDR2, a VH CDR3 and a VL CDR3, or any combination thereof of the VH CDRs and VL CDRs listed in Table 2 and Table 3.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 59, line 33 of the specification:

In one embodiment, an antibody or fragment thereof comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:1, [SEQ ID NO:12 or SEQ ID NO:44] SEQ ID NO:10 or SEQ ID NO:17 and a VL CDR1 having the amino acid sequence of SEQ ID NO:4, [SEQ ID NO:15, SEQ ID NO:38, SEQ ID NO:48, SEQ ID NO:58 or SEQ ID NO:86] SEQ ID NO:13, SEQ ID NO: 21, SEQ ID NO:31, SEQ ID NO: 39, SEQ ID NO:47, SEQ ID NO: 53 or SEQ ID NO: 73. In another embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:1, [SEQ ID NO:12 or SEQ ID NO:44] SEQ ID NO:10 or SEQ ID NO:17 and a VL CDR2

having the amino acid sequence of SEQ ID NO:5, [SEQ ID NO:16, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:41, SEQ ID NO:49, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:63, SEQ ID NO:72, SEQ ID NO:77, SEQ ID NO:91, SEQ ID NO:95 or SEQ ID NO:103] SEQ ID NO:14, SEQ ID NO:22, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69 or SEQ ID NO:72. In another embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:1, [SEQ ID NO:12 or SEQ ID NO:44] SEQ ID NO:10 or SEQ ID NO:17 and a VL CDR3 having the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:[17] 15.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 60, line 9 of the specification:

In another embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:2, [SEQ ID NO:45, SEQ ID NO:52, SEQ ID NO:66, SEQ ID NO:75 or SEQ ID NO:96] SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:37, SEQ ID NO:41 or SEQ ID NO:45 and a VL CDR1 having the amino acid sequence of SEQ ID NO:4, [SEQ ID NO:15, SEQ ID NO:38, SEQ ID NO:48, SEQ ID NO:58 or SEQ ID NO:86] SEQ ID NO:13, SEQ ID NO: 21, SEQ ID NO:31, SEQ ID NO: 39, SEQ ID NO:47, SEQ ID NO: 53 or SEQ ID NO: 73. In another embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:2, [SEQ ID NO:45, SEQ ID NO:52, SEQ ID NO:66, SEQ ID NO:75 or SEQ ID NO:96] SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:37, SEQ ID NO:41 or SEQ ID NO:45 and a VL CDR2 having the amino acid sequence of SEQ ID NO:5, [SEQ ID NO:16, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:41, SEQ ID NO:49, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:63, SEQ ID NO:72, SEQ ID NO:77, SEQ ID NO:91, SEQ ID NO:95 or SEQ ID NO:103] SEQ ID NO:14, SEQ ID NO:22, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69 or SEQ ID NO:72. In another embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:2, [SEQ ID NO:45, SEQ ID NO:52, SEQ ID NO:66, SEQ ID NO:75 or SEQ ID NO:96] SEQ ID NO:18, SEQ

ID NO:24, SEQ ID NO:37, SEQ ID NO:41 or SEQ ID NO:45 and a VL CDR3 having the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:[17] 15.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 60, line 24 of the specification:

In another embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:3, [SEQ ID NO:13, SEQ ID NO:22, SEQ ID NO:32 or SEQ ID NO:46] SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:26 or SEQ ID NO:29 and a VL CDR1 having the amino acid sequence of SEQ ID NO:4, [SEQ ID NO:15, SEQ ID NO:38, SEQ ID NO:48, SEQ ID NO:58 or SEQ ID NO:86] SEQ ID NO:13, SEQ ID NO: 21, SEQ ID NO:31, SEQ ID NO: 39, SEQ ID NO:47, SEQ ID NO: 53 or SEQ ID NO: 73. In another embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:3, [SEQ ID NO:13, SEQ ID NO:22, SEQ ID NO:32 or SEQ ID NO:46] SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:26 or SEQ ID NO:29 and a VL CDR2 having the amino acid sequence of SEQ ID NO:5, [SEQ ID NO:16, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:41, SEQ ID NO:49, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:63, SEQ ID NO:72, SEQ ID NO:77, SEQ ID NO:91, SEQ ID NO:95 or SEQ ID NO:103] SEQ ID NO:14, SEQ ID NO:22, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69 or SEQ ID NO:72. In a preferred embodiment, an antibody of the present invention or fragment thereof comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:3, [SEQ ID NO:13, SEQ ID NO:22, SEQ ID NO:32 or SEQ ID NO:46] SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:26 or SEQ ID NO:29 and a VL CDR3 having the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:[17] 15.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 61, line 3 of the specification:

The present invention also provides for a nucleic acid molecule, generally isolated, encoding an antibody of the invention or fragment thereof. In a specific embodiment, an isolated nucleic acid molecule of the invention encodes an antibody having the amino acid sequence of [SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84,

SEQ ID NO:88 or SEQ ID NO:92] SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, A8c7. Preferably, an isolated nucleic acid molecule of the invention encodes an antibody having the amino acid sequence of [SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7. In another embodiment, an isolated nucleic acid molecule of the invention encodes an antibody comprising a Fab fragment having the amino acid sequence of [SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36 SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:69, SEQ ID NO:73, SEQ ID NO:137, SEQ ID NO:222, or SEQ ID NO:223] 1X-L493L2FR, H3-3F4, M3H9, Y10H6, DG, AFFF, 6H8, L1-7E5, L2-15B10, P12F2, P12F4, P11d4, Ale9, A12a6, A13a11, A13c4, A17d4, or A8c7.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 61, line 17 of the specification:

In another embodiment, an isolated nucleic acid molecule of the invention encodes an antibody fragment having the amino acid sequence of portion of [SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7 that immunospecifically binds to a RSV antigen. In another embodiment, an isolated nucleic acid molecule of the invention encodes an antibody fragment having the amino acid sequence of [SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36 SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:69, SEQ ID NO:73, SEQ ID NO:137, SEQ ID NO:222, or SEQ ID NO:223] 1X-L493L2FR, H3-3F4, M3H9, Y10H6, DG, AFFF, 6H8, L1-7E5, L2-15B10, P12F2, P12F4, P11d4, Ale9, A12a6, A13a11, A13c4, A17d4, or A8c7.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 62, line 28 of the specification:

The present invention also provides antibodies or fragments thereof comprising derivatives of the VH domains, VH CDRs, VL domains, and VL CDRs described herein that immunospecifically bind to an RSV antigen. The present invention also provides antibodies or fragments thereof comprising derivatives of [SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7. The present invention further provides antibodies or fragments thereof comprising derivatives of Fab fragments having the amino acid sequence of [SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36 SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:69, SEQ ID NO:73, SEQ ID NO:137, SEQ ID NO:222, or SEQ ID NO:223] ~~IX-~~ L493L2FR, H3-3F4, M3H9, Y10H6, DG, AFFF, 6H8, L1-7E5, L2-15B10, P12F2, P12F4, P11d4, Ale9, A12a6, A13a11, A13c4, A17d4, or A8c7. Standard techniques known to those of skill in the art can be used to introduce mutations in the nucleotide sequence encoding a molecule of the invention, including, for example, site-directed mutagenesis and PCR-mediated mutagenesis which results in amino acid substitutions. Preferably, the derivatives include less than 25 amino acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2 amino acid substitutions relative to the original molecule. In a preferred embodiment, the derivatives have conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a side chain with a similar charge. Families of amino acid residues having side chains with similar charges have been defined in the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the

resultant mutants can be screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed and the activity of the protein can be determined.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 63, line 25 of the specification:

In a specific embodiment, an antibody or fragment thereof that immunospecifically binds to a RSV antigen comprises a nucleotide sequence that hybridizes to the nucleotide sequence encoding [SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:69, SEQ ID NO:73, SEQ ID NO:78, ~~SEQ ID NO:79~~, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88, SEQ ID NO:92, SEQ ID NO:137, SEQ ID NO:222, or SEQ ID NO:223] SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale109, A12a6, A13a11, A13c4, A17d4, A4B4, A8c7, 1X-493L2FR, H3-3F4, M3H9, Y10H6, DG, 6H8, L1-7E5 or L1-15B10, under stringent conditions, *e.g.*, hybridization to filter-bound DNA in 6x sodium chloride/sodium citrate (SSC) at about 45 °C followed by one or more washes in 0.2xSSC/0.1% SDS at about 50-65 °C, under highly stringent conditions, *e.g.*, hybridization to filter-bound nucleic acid in 6xSSC at about 45 °C followed by one or more washes in 0.1xSSC/0.2% SDS at about 68 °C, or under other stringent hybridization conditions which are known to those of skill in the art (see, for example, Ausubel, F.M. et al., eds. , 1989, *Current Protocols in Molecular Biology*, Vol. I, Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York at pages 6.3.1-6.3.6 and 2.10.3).

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 64, line 5 of the specification:

In another embodiment, an antibody or fragment thereof that immunospecifically binds to a RSV antigen comprises an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of [SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID

NO:36 SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:69, SEQ ID NO:73, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88, SEQ ID NO:92, SEQ ID NO:137, SEQ ID NO:222, or SEQ ID NO:223] SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale109, A12a6, A13a11, A13c4, A17d4, A4B4, A8c7, 1X-493L2FR, H3-3F4, M3H9, Y10H6, DG, 6H8, L1-7E5 or L1-15B10.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 68, line 3 of the specification:

The present invention further provides for compositions comprising one or more antibodies of the invention or fragments thereof. In a specific embodiment, a composition of the present invention comprises one or more antibodies having an amino acid sequence of [SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7. In another embodiment, a composition of the present invention comprises one or more antibodies or fragments thereof comprising a Fab fragment having an amino acid sequence of [SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36 SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:69, SEQ ID NO:73, SEQ ID NO:137, SEQ ID NO:222, or SEQ ID NO:223] 1X-L493L2FR, H3-3F4, M3H9, Y10H6, DG, AFFF, 6H8, L1-7E5, L2-15B10, P12F2, P12F4, P11d4, Ale9, A12a6, A13a11, A13c4, A17d4, or A8c7.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 71, line 4 of the specification:

In one embodiment, a fusion protein of the invention comprises an antibody having the amino acid sequence of [SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7 and a heterologous polypeptide. In another embodiment, a fusion protein of the invention comprises an antibody or antibody fragment having the amino acid sequence of [SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:24, SEQ

ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36 SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:69, SEQ ID NO:73, SEQ ID NO:137, SEQ ID NO:222, or SEQ ID NO:223] 1X-L493L2FR, H3-3F4, M3H9, Y10H6, DG, AFFF, 6H8, L1-7E5, L2-15B10, P12F2, P12F4, P11d4, Ale9, A12a6, A13a11, A13c4, A17d4, or A8c7 and a heterologous polypeptide. In another embodiment, a fusion protein of the invention comprises one or more VH domains having the amino acid sequence of any one of the VH domains listed in Table 2 or one or more VL domains having the amino acid sequence of any one of the VL domains listed in Table 2 and a heterologous polypeptide. In another embodiment, a fusion protein of the present invention comprises one or more VH CDRs having the amino acid sequence of any one of the VH CDRs listed in Table 2 or Table 3 and a heterologous polypeptide. In another embodiment, a fusion protein comprises one or more VL CDRs having the amino acid sequence of any one of the VL CDRs listed in Table 2 or Table 3 and a heterologous polypeptide. In another embodiment, a fusion protein of the invention comprises at least one VH domain and at least one VL domain listed in Table 2 and a heterologous polypeptide. In yet another embodiment, a fusion protein of the invention comprises at least one VH CDR and at least one VL CDR domain listed in Table 2 or Table 3 and a heterologous polypeptide.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 77, line 22 of the specification:

In another embodiment, a mammal, preferably a human, is administered a first dose of a therapeutic or pharmaceutical composition comprising less than 15 mg/kg, preferably less than 10 mg/kg, less than 5 mg/kg, less than 3 mg/kg, less than 1 mg/kg or less than 0.5 mg/kg of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens with higher affinity and/or higher avidity than previously known antibodies (*e.g.*, SYNAGIS®) for the prevention, treatment or amelioration of one or more symptoms associated with a RSV infection in an amount effective to induce a serum titer of at least 1 µg/ml, preferably at least 2 µg/ml, at least 5 µg/ml, at least 10 µg/ml, at least 15 µg/ml, at least 20 µg/ml, or at least 25 µg/ml 20 days (preferably 25, 30, 35, 40 days) after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, the serum titer of said antibodies or antibody fragments is less than 30 µg/ml 30 days after the administration of the first dose and prior to the administration of a subsequent

dose. Preferably, said antibodies have the amino acid sequence of [SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 78, line 1 of the specification:

In another embodiment, a mammal, preferably a human, is administered a first dose of a therapeutic or pharmaceutical composition comprising less than 15 mg/kg, preferably less than 5 mg/kg, less than 3 mg/kg, less than 1 mg/kg or less than 0.5 mg/kg of one or more antibodies or fragments thereof which have increased *in vivo* half-lives and which immunospecifically bind to one or more RSV antigens with higher affinity and/or higher avidity than previously known antibodies (*e.g.*, SYNAGIS®) for the prevention, treatment or amelioration of one or more symptoms associated with a RSV infection in an amount effective to induce a serum titer of at least 1 µg/ml, preferably at least 2 µg/ml, at least 5 µg/ml, at least 10 µg/ml, at least 15 µg/ml, at least 20 µg/ml, or at least 25 µg/ml 25 days (preferably 30, 35, or 40 days) after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, the serum titer of said antibodies or antibody fragments is less than 30 µg/ml 30 days after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, the novel antibodies have the amino acid sequence of [SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 79, line 3 of the specification:

In one embodiment, a mammal, preferably a human, is administered a first dose of a therapeutic or pharmaceutical composition for pulmonary delivery comprising less than 15 mg/kg, preferably less than 5 mg/kg, less than 3 mg/kg, less than 1 mg/kg or less than 0.5 mg/kg, or less than 0.01 mg/kg of one or more antibodies or fragments thereof which immunospecifically bind to one or more RSV antigens with higher affinity and/or higher avidity than previously known antibodies (*e.g.*, SYNAGIS®) for the prevention, treatment

or amelioration of one or more symptoms associated with a RSV infection in an amount effective to induce a titer of 20 ng per mg of lung protein (preferably at least 40 ng/mg, at least 60 ng/mg, at least 80 ng/mg, at least 50 ng/mg, at least 75 ng/mg, at least 100 ng/mg, or at least 150 ng/mg) in an intubation sample or lavage from the lungs of said mammal 20 days (preferably 25, 30, 35, or 40 days) after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, the serum titer of said antibodies or antibody fragments is less than 100 ng/ml of protein 30 days after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, the novel antibodies have the amino acid sequence of [SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7.

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 80, line 16 of the specification:

In one embodiment, a mammal, preferably a human, is administered a first dose of a sustained release formulation comprising less than 15 mg/kg, preferably less than 5 mg/kg, less than 3 mg/kg, less than 1 mg/kg or less than 0.5 mg/kg of one or more antibodies or fragments thereof which immunospecifically bind to one or more RSV antigens with higher affinity and/or higher avidity than previously known antibodies (*e.g.*, SYNAGIS®) for the prevention, treatment or amelioration of one or more symptoms associated with a RSV infection in an amount effective to induce a serum titer of at least 1 µg/ml, preferably at least 2 µg/ml, at least 5 µg/ml, at least 10 µg/ml, at least 15 µg/ml, at least 20 µg/ml, or at least 25 µg/ml for at least 10 days (preferably at least 15, at least 20, at least 25, at least 30, at least 35, or at least 40 days) after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, the serum titer of said antibodies or antibody fragments is less than 30 µg/ml 30 days after the administration of the first dose and prior to the administration of a subsequent dose. Preferably, the novel antibodies have the amino acid sequence of [SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 or A8c7.

A marked up version of the replacement Table 4 showing the changes made relative to Table 4 beginning on page 116, line 6 of the specification:

Table 4. Summary of Kinetic Constants for High Potency Antibodies.

SEQ ID NO.	$K_{on} \times 10^5 (M^{-1}s^{-1})$	$K_{off} \times 10^{-4} (s^{-1})$	EC ₅₀ (nM)
[7] <u>**SYNAGIS®</u>	2.04; 1.89; 2.18	7.64; 7.38; 7.02	3.57
[10] <u>**AFFF</u>	1.08; 0.96; 1.24	2.74; 2.66; 2.06	
[18] <u>*1X-493L2FR</u>	1.85	6.5	
[20] <u>*H3-3F4</u>	4.59; 4.67; 5.72; 6.25; 5.33	4.45; 4.02	
[24] <u>*M3H9</u>	6.05	3.38	
[27] <u>*Y10H6</u>	7.57	4.62	
[30] <u>*DG</u>	2.65; 2.83; 4.16; 3.18; 2.88	1.67; 4.44	
[33] <u>*AFFF</u>	2.12; 1.56; 1.86	2.45; 4.46; 2.68	
[34] <u>*6H8</u>	3.14; 4.44	1.78; 4.73	
[36] <u>*L1-7E5</u>	3.29; 3.57; 4.05; 3.35; 4.26	1.92; 3.31; 2.29	
[39] <u>*L2-15B10</u>	3.69; 2.82; 3.12; 5.33; 3.78	1.34; 4.16; 2.70	
[42] <u>*P12F2</u>	6.63	2.82	0.65
[50] <u>*P12F4</u>	5.27	2.99	0.70
[55] <u>*P11d4</u>	5.70; 5.72	7.17	>20
[60] <u>*Ale9</u>	7.9	4.53	2.5
[64] <u>*A12a6</u>	7.43	2.30	0.62
[69] <u>*A13a11</u>	7.35	2.50	2.04
[73] <u>*A13c4</u>	7.81; 7.35	2.80	0.52

Monoclonal Antibody (**); Fab fragment (*)

A marked up version of the replacement Table 5 showing the changes made relative to Table 5 beginning on page 117, line 1 of the specification:

Table 5.

<u>Monoclonal Antibodies vs Bac-F (1:1)</u>				
	<u>K_{on} (x E+5)</u>	<u>K_{off} (x E-5)</u>	<u>K_D (nM)</u>	<u>Chi2</u>
[P12f2 (SEQ ID NO:78)] <u>P12F2</u>	4.07	12.8	0.31 (13)	0.9
[P12f4 (SEQ ID NO:79)] <u>P12F4</u>	4.95	5.55	0.11 (35)	0.6
A13c4 [(SEQ ID NO:83)]	3.00	3.96	0.13 (30)	1.2
A12a6 [(SEQ ID NO:82)]	4.60	1.65	0.04 (98)	1.2
A1e9 [(SEQ ID NO:81)]	4.33	14.3	0.33 (12)	2.5
A8c7 [(SEQ ID NO:92)]	4.17	8.75	0.21 (19)	1.8
P11d4 [(SEQ ID NO:80)]	4.66	28.9	0.62 (6)	1.0
A17d4 [(SEQ ID NO:84)]	4.56	4.07	0.09 (43)	0.5
[A4b4 (SEQ ID NO:88)] <u>A4B4</u>	4.34	1.06	0.02 (195)	1.5
SYNAGIS® [(SEQ ID NO:7)]	1.32	51.5	3.90 (1)	0.6

A marked up version of the replacement Table 6 showing the changes made relative to Table 6 beginning on page 118 of the specification:

Table 6.

<u>Monoclonal Antibodies vs NUF4 (1:1)</u>				
	<u>Kon (x E+5)</u>	<u>Koff (x E-5)</u>	<u>KD (nM)</u>	<u>Chi2</u>
[P12f2] <u>P12F2</u>	5.41	17.8	0.33 (26)	1.2
[P12f4] <u>P12F4</u>	9.43	22.9	0.24 (36)	0.9
A13c4	3.65	27.2	0.75 (12)	1.8
A12a6	4.00	29.1	0.73 (12)	1.9
A1e9	8.43	58.4	0.69 (13)	0.9
A8c7	8.25	53.5	0.65 (13)	0.7
P11d4	9.04	76.6	0.85 (10)	2.5
A17d4	4.99	36.2	0.73 (12)	2.0
[A4b4] <u>A4B4</u>	4.96	28.2	0.57 (15)	1.9
SYNAGIS®	3.04	265	8.70 (1)	0.4

A marked up version of the replacement Table 7 showing the changes made relative to Table 7 beginning on page 118 of the specification:

Table 7.

<u>Monoclonal Antibodies vs NUF4 (2:1)</u>				
	<u>Kon (x E+5)</u>	<u>Koff (x E-5)</u>	<u>KD (nM)</u>	<u>Chi2</u>
[P12f2] <u>P12F2</u>	2.82	23.6	0.84 (371)	1.5
[P12f4] <u>P12F4</u>	2.73	63.6	2.33 (134)	4.9
A13c4	3.20	22.5	0.70 (446)	1.7
A12a6	2.18	40.8	1.87 (167)	1.9
A1e9	3.29	139	4.22 (74)	2.8
A8c7	4.30	114	2.65 (118)	2.0

P11d4	3.66	313	8.55 (36)	3.6
A17d4	2.64	29.2	1.11 (281)	1.7
[A4b4] <u>A4B4</u>	2.03	40.06	2.00 (156)	1.4
SYNAGIS®	0.78	2420	312 (1)	1.3

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 118, line 35 of the specification:

[SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:69 and SEQ ID NO:73] 1X-493L2FR, H3-3F4, M3H9, Y10H6, DG, *AFFF, 6H8, L1-7E5, L2-15B10, *P12F2, *P12F4, *P11d4, *Ale9, *A12a6, *A13a11, and *A13c4 are Fab fragments having the framework sequences of Figure 1 and the indicated CDR sequences indicated listed in Table 2. [SEQ ID NOs. 7 and 10] SYNAGIS®, AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 and A8c7 are actual monoclonal antibodies with the framework sequences of Figure 1 and constant regions as described in Johnson et al. (1997, Journal of Infectious Diseases 176:1215-1224) and U.S. Patent No. 5,824,307. The framework sequences of these antibodies may differ slightly from those of the Fab fragments.

A marked up version of the replacement Table 8 showing the changes made relative to Table 8 beginning on page 120, line 5 of the specification:

Table 8. End Point RSV Microneutralization Titer Of High On Rate Mutant IgG and Fab

Molecule	Mean IC50 (Curve) µg/ml	STDEV Curve IC50	Fold Difference (Curve ICX50)	Mean IC50 (Control) µg/ml	STDEV Control IC50	Fold Difference (Control IC50)	n (assay repeat)
[Synagis (SEQ ID NO:7)] <u>SYNAGIS</u> ®	0.4527	0.208	-	0.5351	0.238	-	8

**A1e9 [(SEQ ID NO:81)]	0.0625	0.0268	7	0.0645	0.0223	8	3
**A17d4 [(SEQ ID NO:84)]	0.0342	0.022	13	0.0354	0.0187	15	4
**P11d4 [(SEQ ID NO:80)]	0.0217	0.0331	21	0.0289	0.0110	19	5
**[P12f2 (SEQ ID NO:78)] <u>P</u> <u>12F2</u>	0.0231	0.0141	20	0.0223	0.0083	24	6
**A8c7 [(SEQ ID NO:92)]	0.0337	0.0309	13	0.0383	0.0283	14	5
**A12a6 [(SEQ ID NO:82)]	0.0357	0.0316	13	0.0354	0.0261	15	7
**[P12f4 (SEQ ID NO:79)] <u>P12F4</u>	0.0242	0.0163	19	0.0235	0.0076	23	7
**A13c4 [(SEQ ID NO:83)]	0.0376	0.0268	12	0.0375	0.0213	14	6
**[A4b4 (SEQ ID NO:88)] <u>A4B4</u>	0.0171	0.0018	27	0.0154	0.00417	35	2
*A1e9 [(SEQ ID NO:60)]	0.157	-	3	0.125	-	4	1
*A17d4 [(SEQ ID NO:222)]	0.0179	-	25	0.0171	-	31	1
*P11d4 [(SEQ ID NO:55)]	>1.00	-	-	>1.00	-	-	1

*[P12f2 (SEQ ID NO:42)] <u>P12F2</u>	0.0407	0.0112	11	0.0326	0.00905	16	2
*A8c7 [(SEQ ID NO:223)]	0.177	-	3	0.157	-	34	1
*A12a6 [(SEQ ID NO:64)]	0.0287	0.00417	16	0.0310	0.00982	17	2
*[P12f4 (SEQ ID NO:50)] <u>P12F4</u>	0.0464	0.00791	10	0.0351	0.0126	15	2
*A13c4 [(SEQ ID NO:73)]	0.0264	0.00141	17	0.0258	0.00071	21	2
*[A4b4 (SEQ ID NO:137)] <u>A4B4</u>	0.0414	-	11	0.0411	-	13	1
*A13a11 [(SEQ ID NO:69)]	0.120	0.0222	4	0.1022	0.0260	5	2
*A1h5 [(SEQ ID NO:225)]	0.194	0.462	2	0.176	0.0625	3	2

** Monoclonal Antibody

* Fab Fragment

A marked up version of the replacement paragraph showing the changes made relative to the paragraph beginning on page 122, line 11 of the specification:

Antibodies having the amino acid sequence of [SEQ ID NO:83 (JA13c4)], [SEQ ID NO:84 (JA17d4)], [SEQ ID NO:88 (JA4B4)], and [SEQ ID NO:7 (JSYNAGIS®)] were diluted in dialysate and the concentrations were determined by UV spectroscopic absorption measurements with a Perkin-Elmer Lambda 4B Spectrophotometer using an extinction coefficient of 217,000 M⁻¹ cm⁻¹ at the peak maximum at 280 nm. The diluted NUF4 concentrations were calculated from the ratio of the mass of the original sample to that of

the diluted sample since its extinction coefficient was too low to determine an accurate concentration without employing and losing a large amount of sample.

EXHIBIT B

A MARKED UP VERSION OF THE CLAIMS AMENDED IN THE AMENDMENT FILED NOVEMBER 23, 2001

IN U.S. APPLICATION SERIAL NO. 09/724,396
ATTORNEY DOCKET NO. 10271-007

18. (amended) The method of claim 1 or 2, wherein at least one of the antibodies has the amino acid sequence of [SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

44. (amended) The method of claim 19 or 20, wherein at least one of the antibodies has the amino acid sequence of [SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

72. (amended) The method of claim 45 or 46, wherein at least one of the antibodies has an amino acid sequence of [SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

81. (amended) The sustained release formulation of claim 73, wherein at least one of said antibodies at least one of the antibodies has an amino acid sequence of [SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

82. (amended) The pharmaceutical composition of claim 74, wherein at least

one of said antibodies at least one of the antibodies has an amino acid sequence of [SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

139. (amended) The method of claim 123 or 124, wherein at least one of the antibodies has an amino acid sequence of [SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92] SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

179. (amended) The method of claim 156 or 157, wherein at least one of said antibodies comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:1, [SEQ ID NO:12 or SEQ ID NO:44] SEQ ID NO:10 or SEQ ID NO:17, a VH CDR2 having the amino acid sequence of SEQ ID NO:2, [SEQ ID NO:45, SEQ ID NO:52, SEQ ID NO:66, SEQ ID NO:75 or SEQ ID NO:96] SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:37, SEQ ID NO:41 or SEQ ID NO:45, a VH CDR3 having the amino acid sequence of SEQ ID NO:3, [SEQ ID NO:13, SEQ ID NO:22, SEQ ID NO:32 or SEQ ID NO:46] SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:26 or SEQ ID NO:29, a VL CDR1 having the amino acid sequence of SEQ ID NO:4, [SEQ ID NO:15, SEQ ID NO:38, SEQ ID NO:48, SEQ ID NO:58 or SEQ ID NO:86] SEQ ID NO:13, SEQ ID NO: 21, SEQ ID NO:31, SEQ ID NO: 39, SEQ ID NO:47, SEQ ID NO: 53 or SEQ ID NO: 73, a VL CDR2 having the amino acid sequence of SEQ ID NO:5, [SEQ ID NO:16, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:36, SEQ ID NO:41, SEQ ID NO:49, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:63, SEQ ID NO:72, SEQ ID NO:77, SEQ ID NO:91 or SEQ ID NO:95] SEQ ID NO:14, SEQ ID NO:22, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69 or SEQ ID NO:72, or aVL CDR3 having the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:[17] 15.

192. (amended) The method of claim 180 or 181, wherein at least one of the antibodies has an amino acid sequence of [SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID

NO:88 or SEQ ID NO:92] AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

EXHIBIT C
PENDING CLAIMS
AS OF NOVEMBER 23, 2001

IN U.S. APPLICATION SERIAL NO. 09/724,396
ATTORNEY DOCKET NO. 10271-007

1. A method of preventing a respiratory syncytial virus (RSV) infection in a mammal, said method comprising administering to said mammal a dose of a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein said prophylactically effective amount is less than 15 mg/kg of said antibodies or antibody fragments.
2. A method of treating or ameliorating one or more symptoms associated with a RSV infection in a mammal infected with RSV, said method comprising administering to said mammal a dose of a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein said therapeutically effective amount is less than 15 mg/kg of said antibodies or antibody fragments.
3. The method of claim 1, wherein said antibodies or antibody fragments have an affinity of at least $2 \times 10^8 \text{ M}^{-1}$ for RSV antigens.
4. The method of claim 2, wherein said antibodies or antibody fragments have an affinity of at least $2 \times 10^8 \text{ M}^{-1}$ for RSV antigens.
5. The method of claim 1, 2, 3, or 4, wherein the dose is less than 5 mg/kg or less.
6. The method of claim 1, 2, 3, or 4, wherein the dose is 3 mg/kg or less.
7. The method of claim 1, 2, 3, or 4, wherein the dose is 1.5 mg/kg or less.

8. The method of claim 1 or 2, wherein said antibodies or antibody fragments are administered by a nebulizer or inhaler.

9. The method of claim 1 or 2, wherein said antibodies or antibody fragments are administered intramuscularly, intravenously or subcutaneously.

10. The method of claim 1 or 2, wherein said antibodies or antibody fragments administered 1, 2, 3, 4 or 5 times during the RSV season.

11. The method of claim 7, wherein said antibodies or antibody fragments administered 5 times during the RSV season.

12. The method of claim 6, wherein said antibodies or antibody fragments administered 3 times during the RSV season.

13. The method of claim 5, wherein said antibodies or antibody fragments are administered 2 times during the RSV season.

14. The method of claim 1 or 2, wherein at least one of the antibodies is a human or humanized monoclonal antibody.

15. The method of claim 1 or 2, wherein the mammal is a human subject, a human subject which has had a bone marrow transplant, an elderly human subject, or a human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

16. The method of claim 1 or 2, wherein the mammal is a human infant.

17. The method of claim 1, wherein the mammal is a human infant born prematurely or is at risk of hospitalization for a RSV infection.

18. The method of claim 1 or 2, wherein at least one of the antibodies has the amino acid sequence of SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

19. A method of preventing RSV infection in a mammal, comprising administering to said mammal a first dose of a prophylactically effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens, wherein said prophylactically effective amount is a dose of less than 15 mg/kg of said antibodies or antibody fragments, wherein said administration results in a prophylactically effective serum titer of said antibodies or antibody fragments that is less than 30 µg/ml at least 20 days after the administration of said first dose and prior to the administration of a subsequent dose.

20. A method of treating or ameliorating one or more symptoms associated with RSV infection in a mammal with a RSV infection, comprising administering to said mammal a first dose of a therapeutically effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens, wherein said therapeutically effective amount is a dose of less than 15 mg/kg of said antibodies or antibody fragments, wherein said administration results in a therapeutically effective serum titer of said antibodies or antibody fragments that is less than 30 µg/ml at least 20 days after the administration of said first dose and prior to the administration of a subsequent dose.

21. The method of claim 19, wherein said antibodies or antibody fragments bind to a RSV antigen with an affinity constant of at least $2 \times 10^8 \text{ M}^{-1}$.

22. The method of claim 20, wherein said antibodies or antibody fragments bind to a RSV antigen with an affinity constant of at least $2 \times 10^8 \text{ M}^{-1}$.

23. The method of claim 19, 20, 21 or 22, wherein the dose is less than 5 mg/kg or less.

24. The method of claim 19, 20, 21 or 22, wherein the dose is 3 mg/kg or less.

25. The method of claim 19, 20, 21 or 22, wherein the dose is 1.5 mg/kg or less.

26. The method of claim 23, wherein the serum titer is at least 2 µg/ml.
27. The method of claim 24, wherein the serum titer is at least 2 µg/ml.
28. The method of claim 25, wherein the serum titer is at least 2 µg/ml.
29. The method of claim 19, wherein said prophylactically effective serum titer is less than 30 µg/ml at least 30 days after the administration of said first dose and prior to the administration of a subsequent dose.
30. The method of claim 20, wherein said therapeutically effective serum titer is less than 30 µg/ml at least 30 days after the administration of said first dose and prior to the administration of a subsequent dose.
31. The method of claim 21, wherein said prophylactically effective serum titer is less than 30 µg/ml at least 30 days after the administration of said first dose and prior to the administration of a subsequent dose.
32. The method of claim 22, wherein said therapeutically effective serum titer is less than 30 µg/ml at least 30 days after the administration of said first dose and prior to the administration of a subsequent dose.
33. The method of claim 19, wherein the dose is 1.5 mg/kg or less and said prophylactically effective serum titer is at least 2 µg/ml at least 30 days after the administration of said first dose and prior to the administration of a subsequent dose.
34. The method of claim 20, wherein the dose is 1.5 mg/kg or less and said therapeutically effective serum titer is at least 2 µg/ml at least 30 days after the administration of said first dose and prior to the administration of a subsequent dose.
35. The method of claim 21, wherein the dose is 1.5 mg/kg or less and said prophylactically effective serum titer is at least 2 µg/ml at least 30 days after the administration of said first dose and prior to the administration of a subsequent dose.

36. The method of claim 22, wherein the dose is 1.5 mg/kg or less and said therapeutically effective serum titer is at least 2 µg/ml at least 30 days after the administration of said first dose and prior to the administration of a subsequent dose.

37. The method of claim 19 or 20, wherein said antibodies or antibody fragments are administered by a nebulizer or inhaler.

38. The method of claim 19 or 20, wherein said antibodies or antibody fragments are administered intramuscularly, intravenously or subcutaneously.

39. The method of claim 19 or 20, wherein said antibodies or antibody fragments have half-lives in said human subject of greater than 25 days.

40. The method of claim 19 or 20, wherein at least one of the antibodies is a human or humanized monoclonal antibody.

41. The method of claim 19 or 20, wherein the mammal is a human subject, a human subject which has had a bone marrow transplant, an elderly human subject, or a human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

42. The method of claim 19 or 20, wherein the mammal is a human infant.

43. The method of claim 19, wherein the mammal is a human infant born prematurely or is at risk of hospitalization for a RSV infection.

44. The method of claim 19 or 20, wherein at least one of the antibodies has the amino acid sequence of SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

45. A method of preventing a RSV infection in a mammal, said method comprising administering to said mammal a first dose of a prophylactically effective amount

of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein said prophylactically effective amount is approximately 15 mg/kg or less of said antibodies or antibody fragments and a prophylactically effective serum titer is maintained for at least 20 days after the administration said first dose and prior to the administration of a subsequent dose.

46. A method of treating or ameliorating one or more symptoms associated with a RSV infection in a mammal, said method comprising administering to said mammal a first dose of a therapeutically effective dose of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein said therapeutically effective dose is approximately 15 mg/kg or less of said antibodies or antibody fragments and a therapeutically effective serum titer is maintained for at least 20 days after the administration said first dose and prior to the administration of a subsequent dose.

47. The method of claim 45, wherein the antibodies or antibody fragments have an affinity of at least $2 \times 10^8 \text{ M}^{-1}$ for said RSV antigens.

48. The method of claim 46, wherein the antibodies or antibody fragments have an affinity of at least $2 \times 10^8 \text{ M}^{-1}$ for said RSV antigens.

49. The method of claim 45 or 47, wherein said prophylactically effective serum titer is at least 30 $\mu\text{g/ml}$ of said antibodies or antibody fragments.

50. The method of claim 49, wherein said prophylactically effective serum titer is at least 2 $\mu\text{g/ml}$ of said antibodies or antibody fragments.

51. The method of claim 46 or 48, wherein said therapeutically effective serum titer is at least 30 $\mu\text{g/ml}$ of said antibodies or antibody fragments.

52. The method of claim 51, wherein said therapeutically effective serum titer is at least 2 $\mu\text{g/ml}$ of said antibodies or antibody fragments.

53. The method of claim 45 or 47, wherein the prophylactically effective serum titer is maintained for at least 25 days.

54. The method of claim 45 or 47, wherein the prophylactically effective serum titer is maintained for at least 30 days.

55. The method of claim 46 or 48, wherein the therapeutically effective serum titer is maintained for at least 25 days.

56. The method of claim 46 or 48, wherein the therapeutically effective serum titer is maintained for at least 30 days.

57. The method of claim 49, wherein the prophylactically effective serum titer is maintained for at least 25 days.

58. The method of claim 50, wherein the prophylactically effective serum titer is maintained for at least 25 days.

59. The method of claim 49, wherein the prophylactically effective serum titer is maintained for at least 30 days.

60. The method of claim 50, wherein the prophylactically effective serum titer is maintained for at least 30 days.

61. The method of claim 51, wherein the therapeutically effective serum titer is maintained for at least 25 days.

62. The method of claim 52, wherein the therapeutically effective serum titer is maintained for at least 25 days.

63. The method of claim 51, wherein the therapeutically effective serum titer is maintained for at least 30 days.

64. The method of claim 52, wherein the therapeutically effective serum titer is maintained for at least 30 days.
65. The method of claim 45 or 46, wherein said antibodies or antibody fragments are administered by a nebulizer or inhaler.
66. The method of claim 45 or 46, wherein said antibodies or antibody fragments are administered intramuscularly, intravenously or subcutaneously.
67. The method of claim 45 or 46, wherein said antibodies or antibody fragments have half-lives in said human subject of greater than 25 days.
68. The method of claim 45 or 46, wherein at least one of the antibodies is a human or humanized monoclonal antibody.
69. The method of claim 45 or 46, wherein the mammal is a human subject, a human subject which has had a bone marrow transplant, an elderly human subject, or a human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.
70. The method of claim 45 or 46, wherein the mammal is a human infant.
71. The method of claim 45, wherein the mammal is a human infant born prematurely or is at risk of hospitalization for a RSV infection.
72. The method of claim 45 or 46, wherein at least one of the antibodies has an amino acid sequence of SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.
73. A sustained release formulation comprising one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens.

74. A pharmaceutical composition comprising one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens for pulmonary delivery.

75. The sustained release formulation of claim 73, wherein the antibodies or antibody fragments have an affinity of at least $2 \times 10^8 \text{ M}^{-1}$ for said RSV antigens.

76. The pharmaceutical composition of claim 74, wherein the antibodies or antibody fragments have an affinity of at least $2 \times 10^8 \text{ M}^{-1}$ for said RSV antigens.

77. The sustained release formulation of claim 73, wherein at least one of the antibodies or antibody fragments is SYNAGIS® or an antigen-binding fragment thereof.

78. The pharmaceutical composition of claim 74, wherein at least one of the antibodies or antibody fragments is SYNAGIS® or an antigen-binding fragment thereof.

79. The sustained release formulation of claim 73, wherein at least one of said antibodies or antibody fragments is a human or humanized antibody or antibody fragment.

80. The pharmaceutical composition of claim 74, wherein at least one of said antibodies or antibody fragments is a human or humanized antibody or antibody fragment.

81. The sustained release formulation of claim 73, wherein at least one of said antibodies at least one of the antibodies has an amino acid sequence of SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:88 or SEQ ID NO:92.

82. The pharmaceutical composition of claim 74, wherein at least one of said antibodies at least one of the antibodies has an amino acid sequence of SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

83. The sustained release formulation of claim 73, wherein at least one of said antibodies or antibody fragments has an increased *in vivo* half-life.

84. The pharmaceutical composition of claim 74, wherein at least one of said antibodies or antibody fragments has an increased *in vivo* half-life.

85. A method of preventing a RSV infection in a mammal, said method comprising administering to said mammal a prophylactically effective amount of the sustained release formulation of claim 73, 75, 77, 79, 81, or 83.

86. A method of treating or ameliorating one or more symptoms associated with a RSV infection in a mammal with a RSV infection, said method comprising administering to said mammal a therapeutically effective amount of the sustained release formulation of claim 73, 75, 77, 79, 81, or 83.

87. A method of preventing a RSV infection in a mammal, said method comprising administering to the lungs of said mammal a prophylactically effective amount of the pharmaceutical composition of claim 74, 76, 78, 80, 82, or 84.

88. A method of treating or ameliorating one or more symptoms associated with a RSV infection in a mammal with a RSV infection, said method comprising administering to the lungs of said mammal a therapeutically effective amount of the pharmaceutical composition of claim 74, 76, 78, 80, 82, or 84.

89. The method of claim 85, wherein the sustained release formulation is administered intramuscularly, intravenously or subcutaneously.

90. The method of claim 85, wherein the sustained release formulation is administered by a nebulizer or inhaler.

91. The method of claim 86, wherein the sustained release formulation is administered intramuscularly, intravenously or subcutaneously.

92. The method of claim 86, wherein the sustained release formulation is administered by a nebulizer or inhaler.

93. The method of claim 87, wherein the pharmaceutical composition is administered by a nebulizer or inhaler.

94. The method of claim 88, wherein the pharmaceutical composition is administered by a nebulizer or inhaler.

95. The method of claim 85, wherein the mammal is a human subject.

96. The method of claim 86, wherein the mammal is a human subject.

97. The method of claim 87, wherein the mammal is a human subject.

98. The method of claim 88, wherein the mammal is a human subject.

99. The method of claim 95, wherein the human subject has had a bone marrow transplant, is elderly, or has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

100. The method of claim 96, wherein the human subject has had a bone marrow transplant, is elderly, or has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

101. The method of claim 97, wherein the human subject has had a bone marrow transplant, is elderly, or has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

102. The method of claim 98, wherein the human subject has had a bone marrow transplant, is elderly, or has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

103. The method of claim 95, wherein the human subject is an infant.
104. The method of claim 95, wherein the human subject is an infant born prematurely or is at risk of hospitalization for a RSV infection.
105. The method of claim 96, wherein the human subject is an infant.
106. The method of claim 96, wherein the human subject is an infant born prematurely.
107. The method of claim 97, wherein the human subject is an infant.
108. The method of claim 97, wherein the human subject is an infant born prematurely.
109. The method of claim 98, wherein the human subject is an infant.
110. The method of claim 98, wherein the human subject is an infant born prematurely.
111. A method of preventing a RSV infection in a mammal, said method comprising administering to said mammal a first dose of a prophylactically effective dose of SYNAGIS® or an antigen-binding fragment thereof in a sustained release formulation, wherein said prophylactically effective dose is approximately 15 mg/kg or less of SYNAGIS® or an antigen-binding fragment thereof and a prophylactically effective serum titer of at least 30 µg/ml is maintained for at least 20 days after the administration said first dose and prior to the administration of a subsequent dose.
112. A method of treating or ameliorating one or more symptoms associated with a RSV infection in a mammal with a RSV infection, said method comprising administering to said mammal a first dose of a therapeutically effective dose of SYNAGIS® or an antigen-binding fragment thereof in a sustained release formulation, wherein said therapeutically effective dose is approximately 15 mg/kg or less of SYNAGIS® or an antigen-binding

fragment thereof and a prophylactically effective serum titer of at least 30 µg/ml is maintained for at least 20 days after the administration said first dose and prior to the administration of a subsequent dose.

113. The method of claim 111, wherein said prophylactically effective serum titer is maintained for at least 25 days after the administration of the first dose and prior to the administration of a subsequent dose.

114. The method of claim 111, wherein said prophylactically effective serum titer is maintained for at least 30 days after the administration of the first dose and prior to the administration of a subsequent dose.

115. The method of claim 112, wherein said therapeutically effective serum titer is maintained for at least 25 days after the administration of the first dose and prior to the administration of a subsequent dose.

116. The method of claim 112, wherein said therapeutically effective serum titer is maintained for at least 30 days after the administration of the first dose and prior to the administration of a subsequent dose.

117. The method of claim 111 or 112, wherein SYNAGIS® or an antigen-binding fragment thereof is administered by a nebulizer or inhaler.

118. The method of claim 111 or 112, wherein SYNAGIS® or an antigen-binding fragment thereof is administered intramuscularly, intravenously or subcutaneously.

119. The method of claim 111 or 112, wherein SYNAGIS® or an antigen-binding fragment thereof is administered 1, 2, 3, 4, or 5 times during the RSV season.

120. The method of claim 111 or 112, wherein the mammal is a human subject, a human subject which has had a bone marrow transplant, an elderly human subject, or a human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

121. The method of claim 111 or 112, wherein the mammal is a human infant.

122. The method of claim 111, wherein the mammal is a human infant born prematurely or is at risk of hospitalization for a RSV infection.

123. A method of preventing a RSV infection in a mammal, said method comprising administering to said mammal a first dose of a prophylactically effective dose of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens with an affinity of at least $2 \times 10^8 \text{ M}^{-1}$ in a sustained release formulation, wherein said prophylactically effective dose is approximately 15 mg/kg or less of said antibodies or antibody fragments and a prophylactically effective serum titer of less than 30 $\mu\text{g/ml}$ is maintained for at least 20 days after the administration said first dose and prior to the administration of a subsequent dose.

124. A method of treating or ameliorating one or more symptoms associated with a RSV infection in a mammal with a RSV infection, said method comprising administering to said mammal a first dose of a therapeutically effective dose of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens with an affinity of at least $2 \times 10^8 \text{ M}^{-1}$ in a sustained release formulation, wherein said therapeutically effective dose is approximately 15 mg/kg or less of said antibodies or antibody fragments and a therapeutically effective serum titer of less than 30 $\mu\text{g/ml}$ is maintained for at least 20 days after the administration said first dose and prior to the administration of a subsequent dose.

125. The method of claim 123, wherein said prophylactically effective serum titer is at least 2 $\mu\text{g/ml}$.

126. The method of claim 123 or 125, wherein said prophylactically effective serum titer is maintained for at least 25 days after the administration of the first dose and prior to the administration of a subsequent dose.

127. The method of claim 123 or 125, wherein said prophylactically effective serum titer is maintained for at least 30 days after the administration of the first dose and prior to the administration of a subsequent dose.

128. The method of claim 124, wherein said therapeutically effective serum titer is at least 2 µg/ml.

129. The method of claim 124 or 128, wherein said therapeutically effective serum titer is maintained for at least 25 days after the administration of the first dose and prior to the administration of a subsequent dose.

130. The method of claim 124 or 128, wherein said therapeutically effective serum titer is maintained for at least 30 days after the administration of the first dose and prior to the administration of a subsequent dose.

131. The method of claim 123 or 124, wherein said antibodies or antibody fragments are administered by a nebulizer or inhaler.

132. The method of claim 123 or 124, wherein said antibodies or antibody fragments are administered intramuscularly, intravenously or subcutaneously.

133. The method of claim 123 or 124, wherein said antibodies or antibody fragments are administered 1, 2, 3, 4, or 5 times during the RSV season.

134. The method of claim 123 or 124, wherein said antibodies or antibody fragments have half-lives in said human subject of greater than 25 days.

135. The method of claim 123 or 124, wherein at least one of the antibodies is a human or humanized monoclonal antibody.

136. The method of claim 123 or 124, wherein the mammal is a human subject, a human subject which has had a bone marrow transplant, an elderly human subject, or a

human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

137. The method of claim 123 or 124, wherein the mammal is a human infant.

138. The method of claim 123, wherein the mammal is a human infant born prematurely or is at risk of hospitalization for a RSV infection. .

139. The method of claim 123 or 124, wherein at least one of the antibodies has an amino acid sequence of SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

140. A method of preventing a RSV infection in a mammal, said method comprising administering to said mammal a dose of a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens and have increased *in vivo* half-lives, wherein said prophylactically effective amount is a dose approximately 15 mg/kg or less of said antibodies or antibody fragments.

141. A method of treating or ameliorating one or more symptoms associated with a respiratory syncytial virus (RSV) infection in a mammal infected with RSV, said method comprising administering to said mammal a dose of a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens and have increased *in vivo* half-lives, wherein said prophylactically effective amount is a dose approximately 15 mg/kg or less of said antibodies or antibody fragments.

142. The method of claim 140, wherein said antibodies or antibody fragments have an affinity of at least $2 \times 10^8 \text{ M}^{-1}$ for RSV antigens.

143. The method of claim 141, wherein said antibodies or antibody fragments have an affinity of at least $2 \times 10^8 \text{ M}^{-1}$ for RSV antigens.

144. The method of claim 140, 141, 142 or 143, wherein the dose is less than 5 mg/kg or less.

145. The method of claim 140, 141, 142 or 143, wherein the dose is 3 mg/kg or less.
146. The method of claim 140, 141, 142 or 143, wherein the dose is 1.5 mg/kg or less.
147. The method of claim 140, 141, 142 or 143, wherein the increase in *in vivo* half-life is from 21 days to at least 25 days.
148. The method of claim 140, 141, 142 or 143, wherein the increase in *in vivo* half-life is from 21 days to at least 30 days.
149. A method of preventing a RSV infection in a mammal, said method comprising administering to said mammal a dose of a prophylactically effective amount of HL-SYNAGIS or an antigen-binding fragment thereof, wherein said prophylactically effective amount is a dose of approximately 15 mg/kg or less of SYNAGIS® or an antigen-binding fragment thereof which results in a prophylactically effective serum titer that is at least 30 µg/ml at least 30 days after the administration of said first dose and prior to the administration of a subsequent dose.
150. A method of treating or ameliorating one or more symptoms associated with a RSV infection in a human subject infected with RSV, said method comprising administering to said human subject a dose of a therapeutically effective amount of HL-SYNAGIS or an antigen-binding fragment thereof, wherein said therapeutically effective amount is a dose of approximately 15 mg/kg or less of SYNAGIS® or an antigen-binding fragment thereof which results in a therapeutically effective serum titer that is at least 30 µg/ml at least 30 days after the administration of said first dose and prior to the administration of a subsequent dose.
151. The method of claim 149 or 150, wherein said antibodies or antibody fragments are administered by a nebulizer or inhaler.

152. The method of claim 149 or 150, wherein said antibodies or antibody fragments are administered intramuscularly, intravenously or subcutaneously.

153. The method of claim 149 or 150, wherein the mammal is a human subject, a human subject which has had a bone marrow transplant, an elderly human subject, or a human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

154. The method of claim 149 or 150, wherein the mammal is a human infant.

155. The method of claim 149, wherein the mammal is a human infant born prematurely or is at risk of hospitalization for a RSV infection.

156. A method of preventing a RSV infection in a mammal, said method comprising administering to said mammal a dose of a prophylactically effective amount of one or more antibodies or fragments thereof, wherein said antibodies or fragments thereof immunospecifically bind to one or more RSV antigens and have increased *in vivo* half-lives, and wherein said prophylactically effective amount is a dose of approximately 15 mg/kg or less of said antibodies or antibody fragments which results in a prophylactically effective serum titer of less than 30 µg/ml at least 30 days after the administration of said first dose and prior to the administration of a subsequent dose.

157. A method of treating or ameliorating one or more symptoms associated with a RSV infection in a mammal infected with RSV, said method comprising administering to said mammal a dose of a therapeutically effective amount of one or more antibodies or fragments thereof, wherein said antibodies or fragments thereof immunospecifically bind to one or more RSV antigens and have increased *in vivo* half-lives, and wherein said therapeutically effective amount is a dose of approximately 15 mg/kg or less of said antibodies or antibody fragments which results in a therapeutically effective serum titer of less than 30 µg/ml at least 30 days after the administration of said first dose and prior to the administration of a subsequent dose.

158. The method of claim 156, wherein said antibodies or antibody fragments have an affinity of at least $2 \times 10^8 \text{ M}^{-1}$ for RSV antigens.

159. The method of claim 157, wherein said antibodies or antibody fragments have an affinity of at least $2 \times 10^8 \text{ M}^{-1}$ for RSV antigens.

160. The method of claim 156 or 157, wherein the prophylactically effective serum titer is at least $2 \mu\text{g/ml}$.

161. The method of claim 156 or 157, wherein the therapeutically effective serum titer is at least $2 \mu\text{g/ml}$.

162. The method of claim 149, wherein the prophylactically effective serum titer is at least $40 \mu\text{g/ml}$.

163. The method of claim 149, wherein the prophylactically effective serum titer is at least $50 \mu\text{g/ml}$.

164. The method of claim 150, wherein the therapeutically effective serum titer is at least $40 \mu\text{g/ml}$.

165. The method of claim 150, wherein the therapeutically effective serum titer is at least $50 \mu\text{g/ml}$.

166. The method of claim 149, wherein the prophylactically effective serum titer is at least $30 \mu\text{g/ml}$ at least 35 days after the administration of said first dose and prior to the administration of a subsequent dose.

167. The method of claim 150, wherein the therapeutically effective serum titer is at least $30 \mu\text{g/ml}$ at least 35 days after the administration of said first dose and prior to the administration of a subsequent dose.

168. The method of claim 156 or 158, wherein the prophylactically effective serum titer is at least 2 µg/ml at least 35 days after the administration of said first dose and prior to the administration of a subsequent dose.

169. The method of claim 157 or 159, wherein the therapeutically effective serum titer is at least 2 µg/ml at least 35 days after the administration of said first dose and prior to the administration of a subsequent dose.

170. The method of claim 149 or 150, wherein HL-SYNAGIS or an antigen-binding fragment thereof is formulated in a sustained release formulation.

171. The method of claim 156 or 157, wherein said antibodies or fragments thereof are formulated in a sustained release formulation.

172. The method of claim 156 or 157, wherein said antibodies or fragments thereof are administered by a nebulizer or inhaler.

173. The method of claim 156 or 157, wherein said antibodies or fragments thereof are administered intramuscularly, intravenously or subcutaneously.

174. The method of claim 156 or 157, wherein said antibodies or fragments thereof have half-lives in said human subject of greater than 25 days.

175. The method of claim 156 or 157, wherein at least one of the antibodies is a human or humanized monoclonal antibody.

176. The method of claim 156 or 157, wherein the mammal is a human subject, a human subject which has had a bone marrow transplant, an elderly human subject, or a human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

177. The method of claim 156 or 157, wherein the mammal is a human infant.

178. The method of claim 156, wherein the mammal is a human infant born prematurely or is at risk of hospitalization for a RSV infection.

179. The method of claim 156 or 157, wherein at least one of said antibodies comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:10 or SEQ ID NO:17, a VH CDR2 having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:37, SEQ ID NO:41 or SEQ ID NO:45, a VH CDR3 having the amino acid sequence of SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:26 or SEQ ID NO:29, a VL CDR1 having the amino acid sequence of SEQ ID NO:4, SEQ ID NO:13, SEQ ID NO: 21, SEQ ID NO:31, SEQ ID NO: 39, SEQ ID NO:47, SEQ ID NO: 53 or SEQ ID NO: 73, a VL CDR2 having the amino acid sequence of SEQ ID NO:5, SEQ ID NO:14, SEQ ID NO:22, SEQ ID NO:27, SEQ ID NO:32, ~~SEQ ID NO:35~~, SEQ ID NO:43, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69 or SEQ ID NO:72, or a VL CDR3 having the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:15.

180. A method of preventing a RSV infection in a mammal, said method comprising administering to the lungs of said mammal a first dose of a prophylactically effective amount of a composition comprising one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein said prophylactically effective amount results in a prophylactically effective concentration of at least 20 ng per mg of lung protein at least 20 days after the administration said first dose and prior to the administration of a subsequent dose.

181. A method of treating or ameliorating one or more symptoms associated with a RSV infection in a mammal infected with RSV, said method comprising administering to the lungs of said mammal a first dose of a therapeutically effective amount of a composition comprising one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein said therapeutically effective amount results in a therapeutically effective concentration of at least 20 ng per mg of lung protein at least 20 days after the administration said first dose and prior to the administration of a subsequent dose.

182. The method of claim 180, wherein said antibodies or antibody fragments have an affinity of at least $2 \times 10^8 \text{ M}^{-1}$ for RSV antigens.

183. The method of claim 181, wherein said antibodies or antibody fragments have an affinity of at least $2 \times 10^8 \text{ M}^{-1}$ for RSV antigens.

184. The method of claim 180 or 181, wherein said antibodies or antibody fragments have *in vivo* half-lives of greater than 30 days.

185. The method of claim 180 or 181, wherein said antibodies or antibody fragments have *in vivo* half-lives of greater than 30 days.

186. The method of claim 180 or 181, wherein said antibodies or antibody fragments are administered by a nebulizer or inhaler.

187. The method of claim 180 or 181, wherein said antibodies or antibody fragments are administered intramuscularly, intravenously or subcutaneously.

188. The method of claim 180 or 181, wherein at least one of said antibodies is a human or humanized monoclonal antibody.

189. The method of claim 180 or 181, wherein the mammal is a human subject, a human subject which has had a bone marrow transplant, an elderly human subject, or a human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

190. The method of claim 180 or 181, wherein the mammal is a human infant.

191. The method of claim 180 or 181, wherein the mammal is a human infant born prematurely or is at risk of hospitalization for a RSV infection.

192. The method of claim 180 or 181, wherein at least one of the antibodies has an amino acid sequence of AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

193. A method of preventing a RSV infection in a mammal, said method comprising administering to the lungs of said mammal a first dose of a prophylactically effective amount of a composition comprising SYNAGIS® or a fragment thereof, wherein said prophylactically effective amount results in a prophylactically effective concentration of at least 20 ng per mg of lung protein at least 20 days after the administration said first dose and prior to the administration of a subsequent dose.


194. A method of treating or ameliorating one or more symptoms associated with a RSV infection in a mammal infected with RSV, said method comprising administering to the lungs of said mammal a first dose of a therapeutically effective amount of a composition comprising SYNAGIS® or a fragment thereof, wherein said therapeutically effective amount results in a therapeutically effective concentration of at least 20 ng per mg of lung protein at least 20 days after the administration said first dose and prior to the administration of a subsequent dose.

195. The method of claim 193 or 194, wherein SYNAGIS® or an antigen-binding fragment thereof is administered by a nebulizer or inhaler.

196. The method of claim 193 or 194, wherein SYNAGIS® or an antigen-binding fragment thereof is administered intramuscularly, intravenously or subcutaneously.

197. The method of claim 193 or 194, wherein the mammal is a human subject, a human subject which has had a bone marrow transplant, an elderly human subject, or a human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

198. The method of claim 193 or 194, wherein the mammal is a human infant..



199. The method of claim 193, wherein the mammal is a human infant born prematurely or is at risk of hospitalization for a RSV infection.



EL564157764US

POST OFFICE TO ADDRESSEE



**EXPRESS
MAIL**

UNITED STATES POSTAL SERVICE™

ORIGIN (POSTAL USE ONLY)

PO ZIP Code	Day of Delivery <input type="checkbox"/> Next <input type="checkbox"/> Second	Flat Rate Envelope <input type="checkbox"/>
Date In Mo. Day Year	<input type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	Postage \$
Time In <input type="checkbox"/> AM <input type="checkbox"/> PM	Military <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Return Receipt Fee
Weight lbs. ozs.	Int'l Alpha Country Code	COD Fee Insurance Fee
No Delivery <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday	Acceptance Clerk Initials	Total Postage & Fees \$

DELIVERY (POSTAL USE ONLY)

Delivery Attempt	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Mo. Day		
Delivery Attempt	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Mo. Day		
Delivery Date	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Mo. Day		
Signature of Addressee or Agent		
Name - Please Print		

RECEIVED

NOV 26 2001

CUSTOMER USE ONLY

**TO FILE A CLAIM FOR DAMAGE OR LOSS OF
CONTENTS, YOU MUST PRESENT THE ARTICLE,
CONTAINER, AND PACKAGING TO THE USPS
FOR INSPECTION.**

☐ **WAIVER OF SIGNATURE** (Domestic Only): Additional merchandise and services void if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent. (If delivery employee judges that article can be left in secure location) and I authorize that delivery employee's signature constitutes valid proof of delivery.

☐ **NO DELIVERY**

☐ Weekend

☐ Holiday


Customer Signature

FROM: (PLEASE PRINT)

PHONE ()

TO: (PLEASE PRINT)

PHONE ()



FOR PICKUP OR TRACKING CALL 1-800-222-1811

www.usps.gov



Addressee Copy
Label 11-F July 1997